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During my years at medical school it has been one topic that especially interested me; the 
human body immune system. The immune systems impact in our body, with our environment 
and our quality in life. It is a very detailed medical and science field, but there is also so much 
we still don’t yet know about it. So, when I got this opportunity to write a whole master thesis 
about anything, it was an easy choice. I have been working 4 years at the Gastroenterology 
ward in the University Hospital in the North of Norway, where I have seen many interesting 
liver transplanted patients. Each one with their own post transplanted challenges.   
 
Purpose for the assignment:  
There is interest for collecting knowledge from different research on this field which may 
facilitate the development of therapeutic strategies to promote indefinite allograft acceptance, 
while almost eliminating or minimizing the need for immunosuppressive drugs and then 
prevent the side effects many patients gets from immunosuppressive drugs. (1)  
Questions for the assignment:  
How much do we know about the side effects in immunosuppressive drugs? How much does 
it impact patient’s lives? Is it possible to completely withdrawn IS after an organ 
transplantation? Is there a blueprint rule for right medication in liver transplantation? Why is 
the liver so unique?  
 
I want to thank my supervisor Geir Ivar Nedredal giving me the opportunity to dive in to an 
area of knowledge I would never have been achieving had it not been for this thesis. His 
engagement and competence in hepatology and transplantation procedure is unique in our 
country, and especially in the region Northern Norway.  
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Background: There is increasing interest in long-term management issues in liver 
transplantation recipients; quality of life, complications related to extended 
immunosuppressants, natural development of co-morbidities and recurrent disease. IS agents 
are used in induction of the liver transplantation, maintenance of the organ, and reversal of 
organ rejection.(2) 
Aim: A systematic literature search with the purpose of summaries the existing clinical 
research on this specific topic; immunosuppressive medications post-liver transplantation.  
Material and methods: Search method in PubMed; Medical Subject Headings, with the 
terms: ("Liver Transplantation"[Mesh]) AND "Immunosuppression" [Mesh]. The selected 
studies were assessed for scientific quality and relevance for the thesis.  
Results: Steroid-based IS are responsible for a substantial post-LTx morbidity and mortality, 
hence, minimization of its use is of utmost importance to improve patient’s quality of life. 
Because of systemic steroids impact on all organs in the human body and all its side effects 
that increases risk factors of morbidity.(3) It is important to comprehend the hepatic disease 
and the patient, as well as understanding the efficacies and side effects/interactions of IS 
medication. This way the doctor and the patient can strike a balance between suppression of 
rejection and minimization of side effects. The patient group are very complex, and this have 
been shown to be a challenge when it comes to comparing the result on the effect of different 
studies with different immunosuppression’s as the reason for liver failure have a lot to say for 
graft rejection and patient survival, especially for complication accruing with lifelong IS. 
 
Conclusion: LTx recipients are an inherently complex population, with diverse and serious 
underlying medical concerns that have the potential to adversely affect posttransplant 
outcomes, thus would a general IS therapy lead to a greater rejection rate. There is a need for 
more clinical studies, random control trails, that can help us finding the best 





ACR: Acute Cellular Rejection 
AILD: Autoimmune Liver Diseases 
APC: Antigen-Presenting Cell 
AZA: Azatioprin  
CKD: Chronic Kidney Disease 
CNIs: Calcineurin Inhibitors 
CVD: Cardiovascular Disease  
CYA: Cyclosporin  
DC: Dendritic Cell 
EBV: Epstein-Barr Virus 
eGFR: Estimated Glomerular Filtration Rate 
EVR: Everolimus 
GVHD: Graft-Versus-Host Disease 
HCC: Hepatocellular Carcinoma 
HR: Hazard Ratio  
HRQOL: Health-Related Quality of Life 
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IS: Immunosuppression 
ITT: Intent-To-Treat 
LDLT: Living Donor Liver Transplantation 
LFA-1: Leukocyte Function-Associated Antigen-1 
LTx/LT/OLT: Liver Transplantation/Orthotopic Liver Transplantation 
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MMF: Mycophenolate Mofetil 
MS: Metabolic Syndrome 
PSC: Primary Sclerosing Cholangitis 
PTLD: Post-Transplant Lymphoproliferative Disease 
PTMS: Post Transplant Metabolic Syndrome 
RCT: Randomized Controlled Trial 




1 Briefly Summary of Liver Transplantation History  
Improvements in medical care, operative techniques and immunosuppressive therapies have 
led to the fact that more and more patients with decompensated liver disease are treated with 
liver transplantation. Medical care and operative techniques have been improved, but also 
many new immunosuppressive therapies have result in to greater outcome for posttransplant 
patient and graft survival rates. (2)   
Like Laika, the first animal launched into earth orbit, she paved the way for human 
spaceflight, dogs were the first creature liver transplantation was attempted on by C. Stuart 
Welch in Albany Medical College in the year of 1955, and by Jack Connon in California in 
1956. The first human liver transplantation was performed by T.E. Starzl in 1963. It was a 3 
year old child with biliary atresia, who received the liver from another child who died from a 
brain tumour. Sadly, the child had such a massive haemorrhage and died on the operation 
table. Despite improvements in surgical techniques, liver transplantation remained 
experimental until 1970, when 1 year patient survival rate was expected around 25%. (4) 
From the first era of liver transplantation rejection was a rapid complication. None of the first 
patients recovered their health, and the longest survival was 34 days. Early 
immunosuppressive therapy consisted of prednisolone and azathioprine. Despite poor results 
in survival, the surgeons still had faith in liver transplantation therapy, and during the next 
decades trials all over the world tried to improve the selection of donors and recipients, the 
procedure, the post-transplantation medication, and the knowledge about our immune system.   
From the beginning of liver transplantation history, it has been recognized that the liver has 
unique tolerogenic properties. Compared with other solid organs, the liver has lower 
incidence of rejection and it has also the ability to protect other organs form the same donor 
against rejection. (1) 
Theoretically, it will be possible to apply immunosuppression/immunostimulation in the 
perfect balanced way to either achieve immunological indifference or to obtain stable antigen-




2 A short Overview on Liver Transplantation  
It is a surgical procedure that removes a damaged liver and replace it with another healthy 
liver. The liver that are removed does not longer function properly (liver failure), and the liver 
that are transplanted in are a healthy liver from a deceased or living donor.  
The liver performs several critical functions like processing hormones, nutrients and 
medications, and removing bacteria and toxins from the blood. Producing bile and blood clot 
proteins. Preventing infection and regulate immune responses.  
Liver transplantation is a treatment option for people with liver failure, end-stage chronic liver 
disease, often as one of the last treatment options as their condition can’t be controlled with 
other treatments, like primary liver cancer. Liver failure may happen quickly or over long 
period of time. Acute liver failure (fulminant hepatic failure) or chronic liver failure that may 
be caused by many different conditions. The most common is scarring of the liver, cirrhosis, 
and this is also the most frequently cited reasons for liver transplant. The major causes of 
cirrhosis leading to liver failure and liver transplantation is: Hepatitis B and C, Alcoholic liver 
disease, non-alcoholic fatty liver disease, genetic diseases affecting the liver or diseases that 
affects the bile ducts.  
Risk and complications of the procedure: bleeding or blood clots, bile duct complications 
(leaks or shrinking), infections, failure of donated liver, rejection of donated liver, mental 
confusion or seizures. Recurrence of liver disease is also included in long-term complications. 
The number of people with a critical liver disease, waiting for a transplant surgery, has greatly 
exceed the number of available deceased-donor livers. The unique trait about the human liver 
is that it regenerates and returns to its normal size shortly after surgical removal of part of the 
organ, so it is possible for a living-donor liver transplant to be an alternative. Patients 
receiving liver from a living donor have better short-term survival rates than those who have 
received a liver form a deceased-donor. 
The process ahead to liver transplantation is long and highly evaluated. Briefly summarized 
the recipient need to be healthy enough to have the surgery and tolerate the lifelong follow-up 
and post-transplant medications with its side effects. Anti-rejection medications can cause 
many different side effects and the most common are high blood pressure, high cholesterol, 
impaired glucose tolerance and diabetes, bone thinning, headaches, diarrhea and increased 
risk of infections because of the suppression on the immune system.(6) (7) 
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2.1 Liver transplantation in Norway 
There is only one centre in Norway where liver transplantation (LTx) is done, and it is in Oslo 
University hospital Rikshospitalet. In the period 1984 to 2009; 651 LTx were done in 
Norway, and during the last years there have been a great increased in the number of 
surgeries. In the year of 2008; 98 LTx were completed. The median time on the waiting list is 
26 days. The most frequent reason for LTx in Norway is severe liver failure caused by 
primary sclerosing cholangitis (PSC). (8) 
Standard induction therapy after liver transplantation is triple treatment with Solumedrol/ 
Prednisolone, Prograf bid and CellCept. There are some patient groups where the 
immunological risk is higher, as PSC, PBS or autoimmune hepatitis, and these will be treated 
with IL-2 antagonist (Simulect) and high dose Solumedrol in the induction phase. (9) 
 
3 Introduction to the immune system and 
immunosuppression in Liver Transplantation 
There is increasing interest in long-term management issues in liver transplantation recipients; 
quality of life, complications related to extended immunosuppressants, natural development 
of co-morbidities and recurrent disease. The central issue to most organ transplantation is 
suppression of allograft rejection, and we are using immunosuppressive agents in induction, 
maintenance, and for reversal of graft rejection.(2) 
We do now have very powerful immunosuppressive drugs and it is important to learn how to 
best use them. If a stat of proper tolerance can be given in the majority of patient receiving a 
donated liver, it will be a quest for true immunological tolerance in the clinic. Understanding 
the model of alloimmune response will help to understand the medications act.  
The alloimmune responses involve both naive and memory lymphocytes. Dendritic cells (DC) 
of donor and host origin become activated in the graft and the surrounding tissue and goes to 
T-cell areas of secondary lymphoid organs. Here the dendritic cell which bears the antigen 
engage alloantigen-reactive native T-cells and memory T-cells. Antigen-experienced cells 
may also be activated by other cell types than dendritic cells, such as graft endothelium.  
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• Signal 1 – Alloantigen recognition: An antigen on the surface of DC that triggers T cells 
with cognate T-cell receptors. It requires presentation of a foreign alloantigen along with a 
host MHC molecule, presented by the APC. This signal pathway can be aborted by 
antilymphocyte antibodies.  
• Signal 2 – Costimulation: CD80 and CD86 on the surface of the DC engage CD28 on T 
cells. Lymphocyte activation requires stimulation; the T-cell receptor complex is 
internalized and binds to immunophilin which stimulates calcineurin and then activates 
nuclear factor for T-cell activation by removing pyrophosphate. Cyclophilin and FK-
binding protein, are targets of cyclosporine and tacrolimus. Both agents block calcineurin 
and are known collectively as calcineurin inhibitors(CINs). 
• Signal 3 – Clonal expansion: synthesized IL-2 is secreted by T-cells and binds to IL-2 
receptors. This receptor is located on the cell surface in an autocrine fashion and stimulate 
a burst of cell proliferation. The two immunosuppression drugs Dacilumab and 
Basiliximab both blocks this signal. The drug Sirolimus binds to the mechanistic target of 
rapamycin. Azathioprine(AZA) and mycophenolate mofetil(MMF) stop the proliferation 
burst by inhibiting the level of DNA synthesis.  
 
These signals activate three signal transduction pathways, as is shown in figure 1, (a) the 
calcium-calcineurin pathway, (b) the RAS-mitogen-Activated protein (MAP) kinase pathway, 
and (c) the nuclear factor-kB pathway. Pathway (a), (b) and (c) activate transcription factors 
that trigger the expression of many new molecules, including IL2, CD154, and CD25. These 
triggers Signal 3 which is the start of cell proliferation. Cell proliferation also need nucleotide 
synthesis.  
Proliferation and differentiation lead to large numbers of effector T-cells. Together with 
activated B-cells, producing alloantibody against donor HLA antigens, it will only take a few 
days for the immune response to generate the agents of allograft rejection.  
T-cell proliferation is associated with secretion of cytokines, cell-mediated cytotoxicity, 
chemokines and adhesion molecules. All which recruit additional inflammatory cells to the 
graft together with toxic and vasoactive mediators. For decades doctors have controlled this 
step by using glucocorticoids and antilymphocyte antibodies.  
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Figure 1. Three-signal model: individual immunosuppressive drugs and sites of action. The 
signals shown in red, and the immunosuppressive drugs shown in white boxes. (2)   
 
Effector T-cells infiltrate graft and orchestrate an inflammatory response. Effector T-cells, B-
cells, plasma cells, activated macrophages, and increased chemokine expression gives an 
altered capillary permeability, extracellular matrix and deterioration of parenchymal function.  
The antibody-mediated rejection is diagnosed by criteria in clinical, immunologic, and 
histologic characters. Suppression of allograft rejection is the central issue in any organ 
transplantation. (10) In liver transplantation 25-80% of patients present with acute cellular 
rejection and 5-10% develop chronic rejection. (4) In liver transplantation the 
immunosuppression is classified into three phases: induction (initial) phase, maintenance 
phase, treatment of rejection. These phases will be presented below.  
3.1 Induction phase 
During this phase high level of immunosuppression is maintained, and the goal is to induce a 
state where the patient is in acute immunoparalysis. This prevent early cell-mediated reaction. 
The combination of high dose glucocorticoids and calcineurin inhibitors is good prevention 
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for the allograft from acute cellular rejection(ACR). The antilymphocyte therapy also has 
some adverse effects that is necessary to be aware of, like opportunistic infections, post-
transplant lymphoproliferative disease. This therapy could also be used as treatment for 
steroid-resistant rejection episodes. This will be discussed in the later sections. (4) 
 
3.2 Maintenance phase  
Gradually we go from induction phase to maintenance immunosuppression therapy, and 
calcineurin inhibitors are usually the basis. In this phase it is very important to adjust the 
needs for the patient. To take in consider history of rejection or underlaying liver disease. So, 
if the patient has history of frequent ACR we need to boost the blood levels of 
immunosuppression for a longer period. But this is very individually, and some patients are 
doing well with lower levels. It is highly desired that the immunosuppression therapy 
gradually reduces to avoid side effects caused by immunosuppression, but in the same time 
also avoid episodes of rejection. (4) 
 
3.3 Treatment of Rejection  
There are three types of rejection in liver transplantation:  
- Hyperacute rejection, antibody mediated rejection, that can lead to high mortality rate. 
- Acute cellular rejection (ACR), treated with high-dose glucocorticoids in high dose 
bolus or pulse therapy followed by drug tapering.  
- Chronic rejection, the treatment is very limited.  
We can achieve immunosuppression by depleting lymphocytes, diverting lymphocyte traffic, 
or blocking lymphocyte response pathways. And as we use immunsuppressiv drugs there are 
three categories of effect:  
1) Therapeutic effect; supressing rejection.  
2) Undesired consequences of immunodeficiency, infection or cancer. Such as post 
lymphoproliferative disease, which are related more to the intensity of 
immunosuppression than to specific drug agent used.  
3) Non-immune toxicity towards other tissues. This is agent-specific and is often 
related to the drug mechanism. Each class of immunsuppressiv drugs targets 
molecules with physiologic roles in non-immune tissues.  
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4 Classification of Drugs 
Immunosuppression can be achieved in different ways. By depleting lymphocytes, diverting 
lymphocyte traffic or blocking lymphocyte response pathways. And this could also evolve for 
side effects like characteristic infections and cancer. Fortunately, the newer 
immunosuppressive agents have shown results in lower incidence of both cancer and 
opportunistic infections. (10) 
Immunosuppressive drugs include small-molecule drugs, depleting and nondepleting protein 
drugs, fusion proteins, intravenous immune globulin and glucocorticoids.  
 
Table 1. An overview of the most used immunosuppressive drugs in organ transplantation, 
their mechanism on the immune system and adverse effects:  
Medication class   Agent  Mechanism   Adverse effects 
Corticosteroid Prednisolone  ↓prostaglandin and 
leukotriene release.  
Stabilizes lysosomal 
membranes. 
↑AP-DD cells.  




glucose intolerance, psychiatric 
disturbance, peptic ulcer, 
obesity, cushingoid features, 
avascular necrosis, poor wound 
healing, osteoporosis, cataracts, 
and adrenal suppression.   
Calcineurin 
inhibitor (CIN) 
Cyclosporine  ↓phosphatase activity 
of calcineurin → 
↓transcription of IL-2 
→ inhibition of T-
cell activation 
Acute/chronic renal failure, 
neurotoxic effects. HT, obesity, 
hirsutism, gingival hyperplasia. 
Tacrolimus  Acute/chronic renal failure, 
neurotoxic effects, insulin 






Sirolimus  Inhibits mammalian 
target of rapamycin 
→ diminished 
intracellular 
signalling distal to 




oral ulcers, proteinuria, 
peripheral edema, 
hyperlipidemia, acne, 













block synthesis of 
fuanosine nucleotides 
Bone marrow toxicity, 
abdominal pain, diarrhea, 
nausea, vomiting.   
Antiproliferative 
purine analogue 
Azathioprine Inhibits DNA and 
RNA synthesis in T- 
and B-cells. Inhibits 
CD28 co-stimulation 





Basiliximab Antagonizes IL-2 
receptor with 
resultant inhibition of 
IL-2- mediated T-cell 
activation. 




4.1 Corticosteroids, Prednisolone  
Glucocorticoids are agonists of glucocorticoid receptors, and the effects are manly 
transcriptional through DNA-binding and protein-protein interactions of the steroid receptor 
complex. Activator protein 1 and nuclear factor-κB are targeting transcription factors.  
- Decrease the cytotoxic T-cell proliferation and cytotoxicity 
- Inhibit the production and expression of cytokines like IL-1, IL-2, IL6, TNF 
- Block the ability of macrophages to respond to lymphocyte derived signals 
- Depress delayed hypersensitivity 
- To some extent inhibits antibody-dependent cytotoxicity 
- Inhibit production of γ-interferon 
- Decreases local inflammation by decreasing migration of neutrophils and inhibiting 
lysosomal enzyme released by neutrophils.  
- At higher doses they have a receptor-independent effect.  
Adverse effects of corticosteroids: hyperglycemia, increased appetite and weight gain, 
insomnia, osteoporosis, cataract, myopathy, neurological impairment – psychosis, insomnia, 
skin changes, adrenal insufficiency. (4)  
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4.2 Calcineurin Inhibitors (CNIs) 
Early cell cycle inhibitors. Cyclosporin and tacrolimus bot act in a similar fashion; inhibition 
of T-cell activation by binding specific intracellular proteins to form a complex of drug-
protein. This drug-protein complex reduces the phosphatase activity of calcineurin. This 
results in decreased transcription of IL-2.  In 2004, 97% of all liver transplanted patients were 
discharged home with an immunosuppressive regime where a calcineurin inhibitor were 
incorporated. But the calcineurin inhibitors have several major side effects.  
4.2.1 Cyclosporine (CYA) 
For two decades cyclosporine has been a cornerstone of immunosuppression in 
transplantation. The mechanism of a prodrug that engages cyclophilin, an intracellular protein 
of the immunophilin family, and then forming a complex that then engages calcineurin.  
Adverse effect: nephrotoxicity, hypertension, hyperlipidaemia, gingival hyperplasia, 
hirsutism, haemolytic-uremic syndrome and post-transplantation diabetes mellitus. (10) 
4.2.2 Tacrolimus  
Tacrolimus also inhibits calcineurin, but with greater molar potency than cyclosporine, 
because of the creation of a complex by FK506-binding protein 12 (FKBP12).   
The use of this drug has increased steadily, and tacrolimus is now the dominant calcineurin 
inhibitor, but most transplantation programs are exploiting the strength of both CNIs. But the 
therapy also depending on the risk factors in individual patients.  
Adverse effects: hypertension, hyperlipidaemia, risk of rejection which are lower for 
tacrolimus then cyclosporine, but the risk of diabetes and obesity are greater than for 
cyclosporine.  
 
4.3 Cell Cycle inhibitors 
The immunosuppressive effects of cell cycle inhibitors are by inhibiting the mammalian target 
of rapamycin, also called mTOR. The drug engages FKBP12 to create complexes that engage 
and inhibit the target of rapamycin. Preventing cytokine receptors form activating the cell 
cycle, and arresting cell replication, diminishing intracellular signaling distal to the IL-2 
receptor. This prevent the replication of T-cells.  
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Sirolimus and Everolimus were developed for the use with the immunsuppressiv drug 
cyclosporine, but the combination increased nephrotoxicity, hypertension and hemolytic-
uremic syndrome. Sirolimus and tacrolimus can be combined to avoid toxicity. (10) 
Adverse effects: leukopenia, hyperlipidemia, thrombocytopenia, oral ulcers, acne, proteinuria, 
peripheral edema, interstitial pneumonitis. Poor healing of wound infections and hepatic 
artery thrombosis are shown with high-dose use of sirolimus. (2) 
4.3.1 Sirolimus 
Sirolimus (Rapamune, is a macrolide antibiotic and a potent immunosuppressive agent, for 
the first time used for kidney transplantation in 1999. It is structurally similar to tacrolimus; 
binds with a higher affinity, the same target FK-binding protein, but it does not inhibit 
calcineurin. Sirolimus blocks the transductional signal form IL-2 receptor. It then has the 
power of inhibiting T- and B-cell proliferation. The important different from tacrolimus is its 
freedom from neuro- and nephrotoxicity. Sirolimus in triple therapy combination with 
prednisolone and cyclosporine has a very low rejection rate among LTx.  
Sirolimus have been proposed as a good choice for patients with HCC because of its 
antiproliferative activity. But the benefits have not yet been proven in bigger trails. A 
systematic review that included 11 studies shown that Sirolimus use was associated with a 
higher risk for rash, ulcers, infection and a higher rate of discontinuation of therapy, but it was 
not associated with an increased risk of graft failure. (11) 
 
4.3.2 Everolimus 
Everolimus (12) is the hydroxyethyl derivative of Sirolimus, and its mechanism of action is 
via inhibition of mammalian target of rapamycin, also called mTOR. The same mechanism as 
Sirolimus, but compared it has a higher oral availability and lower plasma binding.  
The side effects seem to be related to the dose, but mostly similar to the side effects caused by 
Sirolimus. Most common; anemia, peripheral edema, nausea, diarrhea, elevated s-creatinine, 





Antimetabolites, also called antiproliferative immunosuppressive agents, reduce immune-
mediated graft injury. The mechanism is by reducing the expansion of activated B and T cells. 
The majority of transplant centers are using MMF in conjunction with corticosteroids and 
CNIs for maintenance therapy, in posttransplant first 6 months.  
Use of antiproliferative immunosuppressive agents (AZA and MMF) can be limited by bone 
marrow toxicity. AZA can cause pancreatitis and hepatotoxicity. The side effects of MMF is 
associated with the gastrointestinal tract as vomiting, diarrhea, nausea and abdominal pain.  
4.4.1 Azathioprine (AZA) 
In 1988 Gertrude Elion and George Hitchings received the Nobel Prize for developing 
Azathioprine. It was the first immunosuppressive agent to achieve widespread use in organ 
transplantation. (10) It acts by releasing 6-mercaptopurin, which interferers with DNA 
synthesis.   
AZA is a purine analogue that inhibits DNA and RNA synthesis, specific in rapidly 
proliferating B and T cells. AZA also inhibits CD28 co-stimulation of T lymphocytes.  
 
4.4.2 Mycophenolate mofetil (MMF) 
MMF came into use for liver transplantation in the 1990s. The difference between MMF and 
AZA is that MMF is more selective. It is converted in the liver to mycophenolic acid and 
targets inosine mono-phosphate dehydrogenase. And this ultimately inhibits DNA synthesis 
by blocking the synthesis of guanosine nucleotides.  
Particularly MMF has been used to minimize CNIs drug use in patients with CNI-induced 
renal insufficiency. It has been shown that replacement of CNIs with MMF result in renal 
improvement, as well as improvement in hypertension. 
 
4.5 Antibody-based Drugs 
Interleukin-2 receptor blockers were developed in the 1990s. They are monoclonal antibodies 
that antagonize the IL-2 receptor. This results in inhibition of IL-2 mediated T-cell activation. 
The drugs have minimal side effects due to their selective action and are generally well 
tolerated. This has led to their increasing usage in steroid-sparing and CNI-minimizing 
therapy regimes. (10) 
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Adverse effect: infection, gastrointestinal related upset, and not so common pulmonary edema 
and bronchospasm.  
4.5.1 Basiliximab  
Basiliximab is a chimeric monoclonal antibody against CD25 (IL-2 receptor α chain).  
The mechanism of the drug is that it binds to and blocks the IL-2 receptor α chain on 
activated T cells, depleting them and inhibiting interleukin-2-induced T-cell activation, so it 
prevents T-cell proliferation. The chimeric structure makes the half-lives longer and it is 
better tolerated. Basiliximab has an elimination half-life of 4 ±2 days.  
Antibodies can help to reduce the use of CNI in patients with renal diseases pre-LTx. Or it 
can minimize steroid use. As shown in one report; Basiliximab controlled and prevent steroid-
resistant rejection after LTx in 4 out of 7 children. (11) 
4.5.2 Daclizumab 
Daclizumab is a humanized monoclonal antibody against CD25 (IL-2 receptor α chain).  The 
action is similar to Basiliximab. A nonrandomized study of Daclizumab before engraftment 
with a dose given on day 5 post-LTx shown a much lower rejection rate the first 6 months 
(18% vs. 40 %). It also showed a marked improvement in renal function, no CMV incidence 
increase and less infectious complications than compared with the control group who were 
given standard immunosuppression.  
Daclizumab was removed from the drug-marked in 2009, because of commercial reasons. 
There were no clinical issues identified. (13, 14) 
 
4.6 Newer Immunosuppression Drugs 
Immunosuppressive agents that are still under experimental trails.  
Alemtuzumab: this drug is a humanized monoclonal, complement-fixing anti-CD52 
antibody. B and T lymphocytes express the CD52 on the surface, together with macrophages, 
monocytes and eosinophils. The activation through complement leads to profound 
lymphocyte depletion. It has been approved in treatment of chronic B-cell lymphocytic 
leukaemia, and tried out for solid organ transplantation, and it has been proposed as a method 
to decrease steroid and CNI drug use.  
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Belatacept: this drug is a high affinity fusion protein that binds CD80/86 on APC. CD80/86 
gets prevented from binding to the T-cell, and this blocks the costimulatory pathway. It can 
permit immunosuppression without nephrotoxicity and are given as a monthly infusion. 
Studies have reported an effectiveness in renal transplantation, but it has been related to an 
increased rate of post-transplant lymphoproliferative disorder. This new immunosuppressive 
drug is not yet used in liver transplantation.   
Efalizumab: a humanized monoclonal antibody, against leukocyte function-associated 
antigen-1, LFA-1 witch plays multiple roles in cell migration, cell adhesion, organ rejection 
and stabilization of the APC T-cell complex, making it very effective. The role of this potent 
drug in liver transplantation is still uncertain.  (11) 
 
5 Liver Tolerance  
Human liver allograft compared to other organs have a lower susceptibility, but in addition, 
some liver transplant recipients have all their immunosuppressive drugs completely with-
drawn. These patients are considered as operationally tolerant. Clinical experience indicates 
that elective immunosuppressive(IS) drug weaning is feasible in almost 20% of selected liver 
transplant recipients. (15) 
 
A few patients in Pittsburg have demonstrated operational tolerance after varying periods of 
treatment with continuous IS after LTx. One woman had no immunosuppressive drugs for 15 
years, making her the longest survivor in the world without IS. She didn’t use the drugs be-
cause she misliked the side effects of the drugs. It is not usual for recipients of other organ 
transplantation to be able to not take any immunosuppression without acute or chronic rejec-
tion of the transplanted organ. We know that the liver is a large MHC antigen source and has 
an incredible reparative capability even after sever damage. The scientist Pollard had shown 
that in humans 50% of the circulating Class I MHC antigen in the blood is produced by the 
liver. Soluble forms of these molecules are also synthetized in the liver grafts. (16) 
 
With markedly improved short-term result of LTx and persistently high numbers of long-term 
complications, we focus more and more on minimizing IS therapy as much as possible. Post-
LT morbidity and mortality are often caused of steroid-based IS, and therefore the minimiza-
tion of the use is important for improving patient’s life. We see that the tendency in clinical 
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practice is moved more and more towards a steroid minimized treatment or total steroid with-
drawal(STWD). Since the very beginning of LTx, steroids have been used as IS drugs, be-
cause they are easy to handle and allow control of most rejections at a low cost. But the side 
effects make great impact on the recipient’s life and the active process of graft tolerance. 
Many studies show that STWD is safe in terms of patient and graft survival and that chronic 
rejection incidence is much less concern in LTx than in renal transplantation, but long-term 
follow-up is mandatory to confirm these findings of these patients. STWD have a beneficial 
metabolic effect. But still, STWD remains controversial due to the lack of evidence-based se-
lection criteria, of well-conducted large clinical trials and of long-term follow-up studies 
looking at chronic allograft rejection and graft survival. (3, 17, 18) 
 
Some recipients of LTx may develop immunologic tolerance, but the factors predicative of 
tolerance are not clearly understood. Immunological tolerance is the phenomenon by which 
some patients maintain normal allograft function as well as normal immunological response 
in the absence of IS. 20 to 40% of LTx patients show this potential. (17) 
 
In an intention-to-treat analysis, 24 members of the total population with more than 3 years of 
follow-up after LTx attempted weaning from IS (17.4%). Fifteen (10.9%) were tolerant. Most 
importantly, there were identified 2 easily obtained variables predictive of tolerance: a longer 
period since transplantation and lower stimulation lymphocyte reactivity (expressed as the 
SI). This may be helpful in selecting patients with a potentially high rate of success with IS 
withdrawal. (17)  
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6 Material and Methods 
This Master Assignment is a systematic review, with summarized result of available 
healthcare studies, with the purpose of summaries the existing clinical research on this 
specific topic; immunosuppressive medications post-liver transplantation.  
 
6.1 Search strategy and selection criteria for the literature 
Pertinent literature used in this thesis was assembled and identified through MEDLINE 
database with the help form the search engine PubMed. The period of searching was done in 
March and April 2019. The search were done by using the method of Medical Subject 
Headings(3), and the terms used were: ("Liver Transplantation"[Mesh]) AND 
"Immunosuppression"[Mesh]  
The goal was to get a good overview and identify the different post liver transplantation 
immunosuppressive treatments, which immunosuppressive drugs were used and what were 
the outcome. The filters used in the search were:  
- An adult patient group (age over 19-year-old).  
- The period, twenty years, covering the search, from January 1999 to April 2019.  
- Only articles written in the English language  
- Evaluating human subjects. 
  
With the search method described above, a total of 942 studies were found to be relevant. 
After constricting the articles for covering publish date in the period of the last twenty years 
the numbers of articles were narrowed down to 503 articles. Then the filter for text 
availability were used and narrowed the search down to only free full texts. Resulting in 204 
articles.  
The 204 remaining articles were then collected and screened for relevancy by reading the 
abstract. The articles with only one author were excluded. After retrieving the full text of the 
chosen articles, 77 articles were chosen as eligible and of high relevancy to be used in this 




6.2 Data collection 
After the search for relevant literature and the selection of articles, I then started to collect 
data and information from the remaining 77 articles. The list of the final articles were put in 
the software EndNote X8, a digital library of references.  
Figure 2 present the results of the search process. The final list of studies is attached in the 
end of this thesis (Appendix).  
 
6.3 Selection of articles  
 
Figure 2. A summary of the literature search presented in a PRISMA Flow diagram. Together 
with the selection of studies.(19) 
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7 Main results and discussion.  
The search process is presented in figure 2 above, and the results are shown as a final table-
list of all 77 studies attached to the thesis, Appendix.  
 
The study design of the selected articles where 8 RCT, 11 prospective, 24 retrospective, 14 
cohort, 11 systematic review, 2 cross section, 2 register studies, 3 single case report studies 
and 2 postal survey/questionnaire. The number of patients included in the studies varied a lot 
from just 20 patients to over one thousand, due to what kind of study design and the exposure.  
 
7.1 Rejection rates 
The list of factors that have been shown to negatively affect graft survival in LTx patients are 
long. These factors are usually stratified into donor factors, graft factors and recipient factors. 
It is not possible to estimate rejection rates only form an immunosuppression point of view. 
(2)  
Donor factors: many donor factors can negatively affect graft survival in LTx recipients. The 
most extensive risk factor for graft failure is donor age. Evidence in patients transplanted for 
HCV show a significant decrease in graft and patient survival rates for those with HCV who 
receive liver from older donors. But there is evidence that careful choice of recipients and 
graft form older donors can be used with survival rates comparable with normal population. 
(20) Donors severity of illness has been demonstrated to predict poorer outcome and higher 
rejection rates. Prolonged stay at intensive care units is also a negative factor, together with 
low bicarbonate level and antecedent hypertension and diabetes mellitus. (2) 
Graft factors: graft type is important determinant of graft rejection and patient survival 
prognosis. Donation after cardiac death exposed to ischemia (prolonged cold ischemia time) 
during cardiopulmonary death, have been shown to have worse outcomes compared with 
donation of liver after brain death. (20) Graft macrovesicular steatosis increase prevalence of 
diabetes and obesity in recipient. 
Recipient factors: although the number of LTx recipients over the age of 65 have increased 
2.5-fold, recipient age has shown to worsen posttransplant prognosis. But it is no consensus 




Using steroid protocols rarely gives rejection, but it is followed with many deadly side 
effects. Two meta‑analyses evaluating corticosteroid‑free IS showed no differences in 
mortality or graft survival rates, and demonstrated reduced cholesterol levels, de novo DM, 
CMV-infection and lower rates of HCV recurrence. Rejection rates were increased in 
individual studies in which steroids were not substituted with other IS; but, when steroids 
were replaced, rejection rates were not elevated. Because of these data, many transplant 
centers endeavour to rapidly taper or even completely avoid corticosteroids in LTx therapy. 
Patients undergoing LTx for immunologic liver diseases, such as autoimmune hepatitis, 
sclerosing cholangitis, and primary biliary cirrhosis, may have less chance of long‑term 
success with a steroid‑sparing strategy. (21, 22) 
Type of rejection can be divided into acute rejection, chronical rejection, steroid-resistant 
rejection, graft lost and death. Lymphoproliferative disease. It got estimated in a meta-
analysis were the IS tacrolimus and cyclosporin were compared as primary 
immunosuppressant post-LTx that if 100 patients got treated with tacrolimus vs. cyclosporine 
nine would avoid rejection, seven would have avoid steroid-resistant rejection, five would 
have avoid graft loss and two patients would have avoid death. But additional four patients 
would have developed diabetes. (23) 
  
7.2 Side effects caused by immunosuppression  
The most life-threatening side effects, and those considered most severe, are renal failure. 
Obesity, glucose intolerance and dyslipidemi are also severe because of the increased risk 
factors of cardiac arrest and stroke. (24) Presented in table 1, again shown here in table 2, 
considerably many side effects caused by IS have been assessed.  
 
Table 2. An overview of the most used immunosuppressive drugs used in organ 
transplantation, and their adverse effects:  
Medication class   Agent  Common side effects 
Corticosteroid Prednisolone  Hypertension, dyslipidemi, glucose intolerance, 
diabetes, psychiatric disturbance, peptic ulcer, obesity, 
cushingoid features, avascular necrosis, poorer wound 
healing, osteoporosis, adrenal suppression, cataracts.   
Calcineurin 
inhibitor (CNI) 
Cyclosporine  Acute/chronic renal failure, neurotoxic effects. 
hypertension, obesity, hirsutism, gingival hyperplasia. 
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Tacrolimus  Acute/chronic renal failure, neurotoxic effects, insulin 
resistance, diarrhea, electrolyte disturbances, alopecia, 
thrombotic microangiopathy. 
Cell cycle inhibitor, 
mTOR inhibitor 
Sirolimus  Leukopenia, anemia, thrombocytopenia, oral ulcers, 
proteinuria, peripheral edema, hyperlipidaemia, acne, 




MMF Bone marrow suppression/toxicity, abdominal pain, 
ileus, diarrhea, nausea, vomiting, oral ulceration.   
Antiproliferative 
purine analogue 
Azathioprine Bone marrow toxicity, nausea, vomiting, pancreatitis, 
hepatotoxicity, neoplasia. 
Antibody-based,  
IL-2 receptor block 
Basiliximab Infection, GI-upset, pulmonary edema, bronchospasm 
Dacilizumab  
 
7.2.1 Corticosteroids and HCV 
Cirrhosis caused by HCV infection are the number one indication for people getting LTx in 
the United States. Patients who are liver transplantated because of cirrhosis secondary to 
HCV infection are recommended to have only a low-dose steroid indefinitely, and to taper 
steroids slowly, and if possible total steroid withdrawal. Corticosteroid are in addition to the 
side effects associated with increased HCV replication. The drug may drive replication 
directly, or they may permit more effective replication though IS. (13) (21) (25) 
 
7.2.2 De novo malignancy  
Immunosuppression increases the risk of malignancy, also in liver transplant recipience. De 
novo malignancies meaning new arriving malignancy and cancers, are a major cause of late 
death post LT. Various potentially oncogenic viruses play major roles in causing de novo 
cancers, and preventing measures include reduction of IS to the level compatible with a good 
allograft function and prophylactic measures against viral infections. Patients of older age and 
male sex are associated with a higher risk of malignancy and transplantation of HCC increase 
the risk of non-melanoma skin cancer.  (26, 27) 
 
A retrospective, single-centre analysis with 14,490 person-years of stringent follow-up at 
outpatient clinic, showed that the cancer incidence rates for the LTx recipients were almost 
twice as high as those for the age- and sex-matched general population. Also the underlying 
liver disease can have a role, like alcoholic cirrhosis gave a higher risk than overall standard 
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incidence ratio for all patients. Esophageal cancer and oral cancer were significant higher.  
(26) In Dr. Aguiar’s study de novo malignancies were diagnosed in 126 patients out of 392 
LTx recipients who were followed up for 8,5 years, that’s 32%, and out of these there were 64 
non-melanoma skin cancer and 81 other malignancies. 18 % of the patients stopped receiving 
CNI and were maintained on MMF monotherapy. The study showed significant proof that 
MMF is associated with a lower risk of cancer in LTx recipients compared with maintenance 
IS with CNI. (28)  
Tumour treatment preformed according to accepted guidelines seems adequate. After 
treatment of de novo malignancies patients had a superior 5-year survival rates for renal cell 
carcinoma, colorectal cancer, lung cancer and thyroid cancer are compared with the general 
population. Whereas other tumours were associated with similar or inferior survival rates after 
the cancer diagnosis. (26) 
A retrospective experiment with 609 patients (year 1985-2007) were studying the impact of 
the two calcineurin inhibitors (CNI); cyclosporine (CYA) vs. tacrolimus (29) and how the IS 
affects long-term tumour incidence of de novo malignancy following liver transplantation. 
Multivariate analysis revealed that the significant risk factors were recipient age (HR 1.06), 
male gender (HR 1.73), and tacrolimus-based IS (HR 2.06). But the mechanisms by which 
CNI promote the development and growth of cancer remain poorly understood, but a theory is 
the inhibition of the immune system and then reduction in the human body’s ability to react 
against cancer cells and reaction on their associated antigens. (30) In another study the 
univariate risk factors for developing de novo cancer were; CYA-treatment, time-period of 
LTx, and patients age. The study concluded with that only CYA treatment emerged as an 
independent risk factor, which attributed to more aggressive cancer types. Compared to 
tacrolimus treatment, CYA treatment with C2 monitoring or in younger patients of less than 
50-years-old is associated with a higher incidence of early de novo cancer risk after LTx. (31) 
De novo PTLD means; new occurrence of post-transplant lymphoproliferative disorder and 
EBV-associated PTLD is the most frequently encountered de novo malignancy after LT. It is 
easily treatable with reduction of IS and by chemotherapy (anti-CD20 monoclonal antibody). 




A retrospectively analyse done in England wanted to determine risk factors, clinical 
characteristics, and outcomes of de novo nonlymphoid malignancies in the post-
transplantation period. Of 1140 patients undergoing 1271 LTx, 30 patients (2.6%) developed 
de novo nonlymphoid malignancy. Skin cancers were the most common(n=13), next 
oropharyngeal carcinoma(n=2), bladder carcinoma(n=2), acute leukaemia(n=2), breast 
carcinoma(n=2), and other malignancies(n=9). Although the incidence of de novo 
nonlymphoid malignancy after LTx is low, patients who underwent LTx for alcoholic 
cirrhosis appear to have an increased risk for developing post LTx malignancy. (27)  
7.2.3 HCC recurrence 
Many patients with hepatocellular carcinoma (HCC) are treated with liver transplantation. 
They are at risk of getting tumour recurrence after LTx, that involves an ominous prognosis 
and strict selection criteria of transplant candidates on the basis of tumour features, for 
minimizing the incidence. We also know that the pharmacologic IS required post-LTx can 
accelerate tumour growth. But the possible influence of the different IS schedules and types 
of therapy on HCC patients post LTx have been poorly studied. (22, 33-35) 
A study on the influence of different schedules of IS and many clinical, histologic and 
pathologic factors on HCC recurrence were investigated with univariates and multivariate 
analysis shown that out of 70 consecutive HCC patients who underwent LTx and received 
cyclosporine–based IS, 26 patients associated with steroids, and steroids and azathioprine in 
44 patients did HCC recurred in 10 % of the patients. The study also shown that different IS 
schedules or the cumulative dosage of steroids and AZA did not influence HCC recurrence 
that was associated instead with CsA. But high CsA exposure favours tumour recurrence. 
CsA blood levels are recommended to be kept to the effective minimum in HCC patients. In 
LTx recipients, presence of pathologic and histologic risk factors, should specific IS protocols 
be considered. (33) 
 
7.2.4 Cardiovascular risk  
Obesity and metabolic syndrome are more common in liver transplant recipients than in the 
general population, this makes them at increased risk of CVD, as well as a lower rate of 
patient survival. Cardiovascular diseases are in fact the leading cause of posttransplant 
morbidity and mortality. As clinical health workers working with this patient group we should 
have a direct focus on controlling weight gain in LTx recipients, to make impact on 
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improving long-term outcomes. Smoking history (ever), male or female, hyperlipidaemia and 
serum ferritin levels are not predictive of CVD.(24) 
The effect of IS on CVD after LTx is difficult to interpret. A retrospective study suggested a 
potential benefit of the IS tacrolimus over other immunosuppressants in lowering the risk of 
CVD post-LTx, but not versus cyclosporine. Tacrolimus beneficial effect may reflect the 
reduced incidence and degree of hypertension, hyperlipidaemia, and renal injury compared to 
other IS. It may be hypothetically plausible that CYA can induce endothelial dysfunction and 
TAC may have a beneficial effect on endothelial function. (24) In a 2 years RCT study, from 
2018, there were found evidence that the risk of major cardiac events increases with 
deteriorating renal function post LTx. This establish the need for careful CV risk management 
in patients with renal impairment. IS based on everolimus with TAC withdrawal, or to a lesser 
amount TAC reduction, improved both renal function and decreased the risk of major CV 
events compared to standard TAC therapy in LTx recipients. (36) Another RCT study, from 
2017, including 719 patients randomized in to three treatment groups; Everolimus + reduced 
Tacrolimus (n = 245), (2) TAC control group(n=243) and (3) TAC elimination (n = 231). The 
results shown a mean increase in weight from baseline was higher at month 12 in the TAC 
control arm (8.15 ± 9.27 kg) than in the EVR + reduced TAC (5.88 ± 12.60 kg, p=0.056) and 
the TAC elimination arms (4.76 ± 9.94 kg, p=0.007). Then after 2 years, the TAC control arm 
displayed a significantly greater weight increase (9.54 ± 10.21 kg) than either the EVR + 
reduced TAC (6.69 ± 8.37 kg, P = 0.011) or the TAC elimination groups (6.01 ± 9.98 kg, P = 
0.024). Rates of post-transplant metabolic syndrome were similar for the EVR + reduced 
TAC (71.8%), TAC elimination (70.3%) and TAC control (67.4%). (37) 
Gastroenterologist George Therapondos did a prospective randomized trial to investigate the 
cardiac function of patients on tacrolimus compared with those on cyclosporin IS post-LTx. 
40 adult LTx recipients with cirrhosis were randomized either to TAC or CYA + AZA + 
prednisolone-based immunotherapy. All had detailed clinical, biochemical, 
electrocardiographic and echocardiographic assessments at regular intervals, followed up 
within 3 months. Abnormalities in cardiac function were common after LTx and significant 
deterioration in left ventricular diastolic function was demonstrable up to 3 months in both 
patient groups. Cardiac function was similar in both groups. Reduced heart rate variability 
(HRV) and higher mean BNP were identified in the TAC group. The percentage increase in 




7.3 Quality of life 
As the survival rates following liver transplantation are rising, health-related quality of life is 
getting increased focus. Numerous studies have shown that health-related quality of life 
improves significantly after live transplantation and that LTx-recipients report gains mostly in 
the aspects of health-related quality of life affected by physical health, but not so much 
improvements in areas affected by psychological functioning. (32, 38, 39) 
 
In a retrospective study done in Germany they found that liver transplant recipients surviving 
more than 15 years post-LTx scored lower in comparison to the German reference population 
in all categories; physical functioning, role physical, general health, vitality, social 
functioning and role emotional. But recipients scored similarly to the reference population in 
the categories; mental health and bodily pain.  
For LTx patients, job rehabilitation after LTx gave a positive effect on quality of life. Patient 
who returned to their job during the first year after the transplantation scored significantly 
higher in the categories of physical functioning and role physical. Occupational rehabilitation 
was the only factor that did have significant positively impact for the long-term survivors.  
Patients marital status didn’t have statistically significant effect on quality of life. Rather 
didn’t the immunosuppression neither. (38)  
Professor Jan Lerut are saying that Steroid-based IS are responsible for a substantial post-LTx 
morbidity and mortality, hence, minimization of its use is of utmost importance to improve 
patient’s quality of life. Because of systemic steroids impact on all organs in the human body 
and all its side effects that increases risk factors of morbidity. (3) 
 
However, it has not been done any good research focusing on LTx-recipients’ quality of life 
post transplantation, or throughout the years after transplantation. Therefore, more systematic 
knowledge, qualitative interview, and survey would be an interest for the future.  
 
7.4 The perfect immunosuppressive combination?  
As discussed earlier in this thesis, the goal of immunosuppressive therapy is to prevent 
allograft rejection, optimize the function of the donated graft, and maximize patient survival 
rates as well as patient’s quality of life while concomitantly maintaining immunologic control 
over neoplasia, infections and minimizing the side effects and their sequelae.  
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IS used in induction therapy (initiated immediately posttransplant and continued for 1-2 
weeks) are most often two or three drugs and most commonly a glucocorticoid, a calcineurin 
inhibitor, and an antimetabolite. IS used after the induction phase, the maintenance therapy, 
use calcineurin inhibitor, mostly tacrolimus, as the cornerstone. But clearly management of 
LTx recipients is an important, diverse and ever-evolving effort.  
It is important to comprehend the hepatic disease and the patient, as well as understanding the 
efficacies and side effects/interactions of IS medication. This way the doctor and the patient 
can strike a balance between suppression of rejection and minimization of side effects.  
7.5 A life without immunosuppressive  
Some patients after liver transplantation might develop immunologic tolerance and then they 
might be able to stop taking immunosuppressants. Attempts on stopping IS treatment is not 
yet recommended because of the risk of graft rejection and that we still don’t have a clear list 
of which patients who would be a good candidate for IS withdrawal. If a liver transplanted 
patient today stops with IS, without medical supervision, it is most likely to have fatal 
rejections then immunologic tolerance, including patients who are many years post-OLT. 
Patients are therefore never recommended to stop all immunosuppression. (40)(3) 
An interesting study with 24 patient who had side effects form IS and were at high risk for 
developing de novo malignancy, without autoimmune disease or active viral hepatitis, 
underwent gradual reduction of their IS. After 14 months of follow up 15 patients (63%) were 
considered to be tolerant because their liver function tests were normal. The other 9 patients 
didn’t get completely withdrawn because of abnormal liver function test. 2 patients of these 9 
had graft rejection shown on liver biopsy and was treated with glucocorticoids. (17) 
 
7.6 A unique organ 
Liver failure is a serious condition and warrants a multimodal approach. For a failing liver 
from either acute liver failure or decompensated liver failure is the best option; liver 
transplantation. Acute liver failure may include progression to hepatic coma and then 
possibility of cerebral herniation. Patients who have poor prognosis have etiologist like drug-
induced acute liver failure, hepatitis B and idiopathic cases. (41) These have approximately 
only 25% spontaneous survival rates. In Norway 25–30 thousand people have HBV infection, 
mostly immigrants who were infected as children back in their home country. Worldwide 
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HBV is one of the most common infections, and approximately 40 presents of the world 
population have been infected by HBV, 350 million people. More than 600 thousand deaths 
each year are calculated caused by HBV-infection causing fulminant hepatitis, cirrhosis and 
liver cancer. HCC is one of the then most common types of cancer worldwide, and we expect 
that 78% of HCC are caused by HBV and HCV. People living in Southeast Asia, South 
America, The Middle East, Eastern Europe, and the tropical areas of Africa have the highest 
prevalence of HBV infections. (42) These are also patients who would never be cured with 
liver transplantation and IS therapy. 
Different approaches to liver failure are being evaluated and some promising including cell 
transplantation and the application of extracorporeal liver support (like dialysis for kidney 
failure). These approaches are relevant for acute liver failure, because a complete recovery 
will not impose sequelae such as lifelong IS with LTx. The treatment with extracorporeal 
support (biologic or nonbiologic systems) aim in the setting of decompensated cirrhosis, 
returning the patient to a compensated state. But it will not offer the possibility of cure. A 
failing liver may not regenerate or recover completely but it can buy time to bridge to a 
lifesaving LTx. As the waiting lists for LTx increases, and an expansion of indications for 
transplantation, and the mortality rates remains high, interest in liver-assist devices is great. 
(41) Maybe extracorporeal or hepatocyte transplantation are the future of life saving treatment 
for patient with liver failure, as today the waiting lists for liver transplantation unfortunately 
outpaced the number of organs available.  
 
7.7 Limitation of the thesis 
The topic for this thesis is wide and during the work with this thesis answering the research 
question have evolved to be more and more complex. The patient group are very complex, 
and this have been shown to be a challenge when it comes to comparing the result on the 
effect of different studies with different immunosuppression’s as the reason for liver failure 
have a lot to say for graft rejection and patient survival. And especially for the complication 
accruing with lifelong IS-therapy. This made it difficult to systemise the result form the 
literature. There is lack of good randomized control trails examine the different effects of IS. 
There are ethical issues preventing RCT because of the high mortality rates in this patient 
group. Most articles found in the literature search were retrospective studies, and the number 
of patients included in the studies were mostly under 150.    
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8 Conclusion  
Minimization, as well as comprehensive management, of early and late posttransplant 
vascular, biliary, immunologic, infectious, metabolic, cardiovascular, and neoplastic 
complications can sustain patient and graft survival rates and optimize patient’s quality of life. 
LTx recipients are an inherently complex population, with diverse and serious underlying 
medical concerns that have the potential to adversely affect posttransplant outcomes, thus 
would a general IS therapy lead to a greater rejection rate. But clinical studies have given us 
some recommendation.  
Tacrolimus remains the mainstay of IS in many centers. But IS based on everolimus with 
TAC withdrawal, or to a lesser amount TAC reduction, improved both renal function and 
decreased the risk of major CV events compared to standard TAC therapy in LTx recipients. 
EVR vs TAC gives an attenuated weight gain over 1- and 2-years post LTx. TAC based IS 
may increase the risk of de novo malignancy. 
 
For patients with pretransplant renal failure in whom we wish to minimize the use of CNI, 
generally use antibody preparations in the immediate post-transplant period along with 
delayed calcineurin inhibitors. Slowly worsening renal disease in the late post-orthotopic liver 
transplant period can be managed by reducing the CNI dose, with the addition of MMF, or by 
switching to sirolimus or everolimus.  
Mycophenolate may also lead to lower long-term risks for de novo cancers. Patients who 
underwent LTx for alcoholic cirrhosis appear to have an increased risk for developing post 
LTx malignancy. The standardized incidence ratio of malignancy in LTx patients compared to 
the general population was 2.2. 
Some patients will develop immunologic tolerance following LTx and may be able to stop 
taking IS. However, because of the risk of irreversible graft rejection, and because of lack in 
tools to assess which patients that are good candidates for IS withdrawal, we never 
recommend complete cessation of immunosuppression. 
There is a need for more clinical studies, random control trails, that can help us finding the 
best immunosuppressive treatment for liver transplanted patients.    
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a Association Between 
Renal Dysfunction 
and Major Adverse 
Cardiac Events After 
Liver 
Transplantation: 
Evidance from an 
International 































events after liver 
transplantation 
719 patients were 
randomized and 




231, TAC Controls 
243) 
By month 24 post-
transplant, 32/716 
patients had major 
cardiac event (4.5%): 
4.1%, 2.2%  and 7.0%  
of patients in the 
EVR/rTAC, TAC 
Elimination and TAC 
Control groups, 
respectively(p=0.043). 
The cumulative eGFR 
was 119 706, 123 082, 
and 105 946 mL in the 
EVR/rTAC, TAC 
Elimination, and TAC 
Control groups, 
respectively, 
corresponding to a mean 
eGFR AUC of 82.4, 
83.0, and 71.9 
mL/min/1.73 m2. Mean 
eGFR AUC was 
inversely associated with 
time to first major 
cardiac event: (p<0.001) 
Immunosuppressive 
regimen based on 
everolimus with 
tacrolimus withdrawal, or 
to a lesser extent 
tacrolimus reduction, 
improves both renal 
function and the risk of 
major cardiac events 
compared to standard 
treatment with tacrolimus. 
Selection of an 
everolimus-based 
immunosuppressive 
regimen may be 
advantageous in avoiding 
major cardiac events in 
liver transplant recipients 













 Low Total Dose of 
Anti-Human T-
Lymphocyte Globulin 
(ATG) Guarantees a 
Good Glomerular 
Filtration Rate after 










cohort study of 
adult LT 
















Evaluate the safety 













Adult patients on 
the waiting list for 
LT from brain-dead 














ATG compared to BAS-
group; no differences 
were found between 
groups regarding age, 
sex, primary liver 
disease, comorbidities. 
50% had recovered their 
renal function at day 7 
after LT, continuing 
with the same 
percentage 1 month after 
LT in the ATG group. 
40% of patients 55% had 
recovered their renal 
function at day 7 and 1 
month after LT, 
respectively, in the BAS 
group; these differences 
were not significant 
between groups. 
The greatest benefit of the 
use of low-dose ATG as 
induction therapy was the 
significant financial saving 
due to the direct cost of 
the drug compared to 
Basiliximab.  
The major limitations of 
this study were the low 
number of patients owing 
to the exploratory nature 











 Tacrolimus Granules 
for Oral Suspension 
as Post-Transplant 
Immunosuppression 
in Routine Medical 














of use of 
tacrolimus 
granules. 
Currently, there are 
no data describing 





61 patients included, 
55.7% were children 
(mainly kidney graft 
recipients) and 
44.3% were adults 
(mostly lung graft 
recipients). 
A 6-month follow-up 
period is a limited 
timespan for the 
observation of long-term 
outcomes regarding 
effectiveness and safety. 
Nevertheless, the results 
observed during this 
period did not differ 
meaningfully from those 
published in clinical 
trials. 
Results suggest that 
tacrolimus granules are 
well tolerated and 
effective in preventing 
transplant rejection when 
administered in routine 
















Therapy and Brain 


























therapy in standard 
dosage present 
increased numbers 






and show impaired 
cognitive function 
compared with 
patients receiving a 
reduced CNI dose, 
patients with CNI-
free IS and controls 
85 patients, (65.9%] 
male) in whom OLT 
had been performed 
approximately 10 
years ago (median, 
10 years; IQR, 8.0-
13.5 years) were 
included. 
In the neurological 
examination, tremor was 
detected in 5 (6%) of 85 
patients. Otherwise, the 
neurological status was 
normal in all patients. 
Considering the median 
results, the patients with 
a CNI-free 
immunosuppression did 
not differ from controls 
in any domain of the 
RBANS. 
The regression analysis 
showed that CNI therapy 
is a negative independent 
prognostic factor for 
cognitive function. 
The results indicate that 
longterm CNI therapy 
after OLT may induce 
both cognitive dysfunction 
and structural brain 
alterations. 
As long as transplant 
function is preserved, 
patients showing CNI 
toxicity early after OLT 
might benefit from a 
change to CNI-free 
immunosuppression in the 
long term because 
cognitive dysfunction 
might impair patients’ 
everyday life, job-related 
performance, and health-














 Everolimus Is 
Associated With Less 
Weight Gain Than 
Tacrolimus 2 Years 








Weight gain early 
after transplant is a 
















After a run-in 
period, patients (N = 
719) were 
randomized at 30 ± 
5 days 
posttransplant in a 
1:1:1 ratio to 3 
treatment groups: (i) 
everolimus (12) + 
reduced tacrolimus 
(29) (n = 245); (ii) 
TAC control (n = 
243) or (iii) TAC 
elimination (n = 
231).  
Mean increase in weight 
from baseline was higher 
at month 12 in the TAC 
control arm (8.15 ± 9.27 
kg) than in the EVR + 
reduced TAC (5.88 ± 
12.60 kg) and the TAC 
elimination arms (4.76 ± 
9.94 kg). At month 24, 
the TAC control arm 
displayed a significantly 
greater weight increase 
(9.54 ± 10.21 kg) than 
either the EVR + 
reduced TAC (6.69 ± 
8.37 kg) or the TAC 
elimination groups (6.01 
± 9.98 kg, P = 0.024). 
Rates of PTMS were 
similar for the EVR + 
reduced TAC (71.8%), 
TAC elimination 
(70.3%) and TAC 
control (67.4%). 
EVR with reduced-
exposure TAC attenuated 
weight gain at 1 and 2 
years posttransplant 
compared with a standard 
TAC immunosuppression 
regimen. Rates of PTMS 
were comparable between 





















Proceedings of the 
National Academy of 
Sciences of the 









T-cell responses in 
humans. However, 
CNIs also reduce 




this negative effect 
and the mechanisms 
responsible remain 
to be elucidated.  
37 liver transplant 










CNIs compromise the 
overall Treg 
immunoregulatory 
capacity to a greater 
extent than would be 
predicted by the 
reduction in the size of 
the Treg compartment, 
given that they 
selectively promote the 
apoptosis of the resting 
and activated Treg 
subsets that are known 
to display the most 
powerful suppressive 
function.  
Current data indicate that 
CNIs do not interfere with 
the capacity of IL-2 to 
expand Tregs. Tthe 
combination of reduced 
levels of CNIs and low-
dose IL-2 is likely to 
constitute an optimal 
immunosuppressive 
regimen to restrain Teffs 
while at the same time 
promoting Treg expansion 










i Clinical and 
microbiological 
epidemiology of early 
















center study,  
There is limited 
literature describing 









study reports on the 
rate and timing of 
these syndromes 




The study was 








recipients of heart, 
lung, liver, kidney, 




0.43 episodes per 1000 
transplant-days, with 
85% occurring >6 
months post-TLx. The 
most frequent infectious: 
respiratory (27%), sepsis 
/bacteremia (13%), liver 
or biliary tract (12%), 
genitourinary (12%), and 
cytomegalovirus related 
(9%). 53% presented 
without fever, 45% had 
no pathogen isolated, 
and multidrug-resistant 
organisms were isolated 
in 27%. 
The increase in the burden 
of infectious 
complications may be 
related to the concurrent 
use of more potent 
immunosuppressive agents 
early post-transplantation 
along with more 
aggressive maintenance 
immunosuppressive 
strategies to prevent acute 
graft dysfunction. The 
most frequent 
hospitalizations were 
attributable to respiratory, 
sepsis or bacteremia, liver 
and biliary, urinary tract, 





























and risk factors 




recipients with a 
survival higher 
than 3 months 
and a mean 




increases the risk of 
malignancy in liver 
transplant 
recipients. The 




this risk has not 
been studied. 
392 patients. 
Recorded data: age, 
sex, smoking, 
indication of liver 
transplantation, and 
MELD score. 




hepatitis C cirrhosis, 
3)and others. The 
presence/absence of 
HCC was also 
recorded 
Older age and male sex 
were also associated 








monotherapy is associated 
with a lower risk of cancer 
in liver transplant 













 A Novel Immune 
Function Biomarker 
Identifies Patients at 













whether a novel 
immune biomarker 





c (IFNc) after 
stimulation with a 
lyophilized ball 
containing an 
adaptive and innate 
immune stimulant 
can predict events 
following 
transplantation. 
75 adult transplant 
recipients 
55/75 (73.3%) patients 
experienced a total of 89 
clinical events. Most 
events occurred within 
the first month. Low 
week 1 results were 
significantly associated 
with risk of early 
infection was associated 
with the highest risk for 
infection with minimal 
rejection risk. 
Low IFNc suggesting 
oversuppression is 
associated with infections, 
whereas high IFNc 
indicating 
undersuppression is 
associated with rejection. 
This assay offers the 




could fundamentally alter 


















 Systematic review: 
recurrent 
autoimmune liver 









frequency and risk 
factors associated 
with recurrent 
AILD post-LT and 
provide 
recommendations 
to reduce the 
incidence of 
recurrence based on 
levels of evidence. 










‘LT’ and ‘recurrent 
disease’. 
Management 
strategies to reduce 
recurrence after LT 
were classified 
according to grade 
and level of 
evidence. 
Survival rates post-LT 
are approximately 90% 
and 70% at 1 and 5 years 
and recurrent disease 
occurs in a range of 10–
50% of patients with 
AILD. Recurrent AIH is 
associated with elevated 
liver enzymes and IgG 
before LT, 
lymphoplasmacytic 
infiltrates in the explants 
and lack of steroids after 
LT (Grade B). 
Tacrolimus use is 
associated with 




with reduced risk of 
PBC recurrence (all 
Grade B). 
Recommendations based 
on grade A level of 
evidence are lacking. The 
need for further study and 
management includes 
active IS before liver 
transplantation and steroid 
use after liver 
transplantation in 
autoimmune hepatitis; 
selective IS with 
ciclosporin and preventive 
ursodeoxycholic acid 











 Complete Hepatitis B 
Virus Prophylaxis 
Withdrawal in 








Cohort study We report the 
results of complete 
HBV prophylaxis 
withdrawal after a 
followup of at least 
6 years in LT 
recipients with 
undetectable serum 
HBV DNA and 
intrahepatic total 
HBV DNA and 
covalently closed 
circular DNA at 
LT. 
We included 30 
HBsAg positive, 
hepatitis B e 
antigen–negative 
recipients, 6 with 
hepatitis C virus and 
7 with hepatitis D 
virus coinfection, 
who had received 
HBIG plus NA for 
at least 5 years after 
LT 
At the end of follow-up, 
90% of patients were 
still prophylaxis-free, 
93.3% were HBsAg 
negative, and 100% 
were HBV DNA 
negative; 60% had anti-
HBs titers >10 IU/L 
(median, 143; range, 13-
1000). 
This small series shows 
that complete prophylaxis 
withdrawal is safe in 
patients transplanted for 
HBV-related disease at 
low risk of recurrence and 
is often followed by 
spontaneous anti-HBs 
seroconversion. Further 
studies are needed to 







 Efficacy and Safety of 
a Steroid-Free 
Immunosuppressive 










efficacy and safety 












steroids after LT 
were enrolled in the 
steroid-free group. 
Compared with 132 
“steroid group” 
In the steroid-free group, 
the patients who fulfilled 
the Milan criteria had 
higher overall and 
tumor-free survival rates 
than those in the steroid 
group (p<0.001). The 
prevalence of HBV 
recurrence (3.0% vs 
13.6%, p=0.02) was 
significantly lower in the 
steroid-free group 
compared with the 
steroid group. 
After LT, an 
immunosuppressive 
regimen without steroids 
could be a safe and 
feasible treatment for 
HBV-related HCC 
patients, thus resulting in 
the reduction of HBV 
recurrence. Based on the 
observed survival rates, 
patients who fulfill the 
Milan criteria may derive 



















prevalence and the 
impact of obesity and 
immunosuppression 




















recipients aged 8–30 
years using National 





matched by gender, 
race/ethnicity, and 
age with 235 
controls from 
NHANES 
Among LT recipients, 
the adjusted odds of IGT 
doubled for every 7.5 
years on calcineurin-
inhibitors (CNIs, OR 
2.10, 95% CI 1.06–4.17 
per 7.5 years on CNIs, 
p=0.03). Among all 
subjects with IGT, LT 
recipients had a lower 
prevalence of 
overweight/obesity and 
less insulin resistance 
(HOMA-IR) than 
controls with IGT. 
Among normal weight 
subjects, LT recipients 
were significantly more 
likely than controls to 
have pre-
hypertension/hypertension, 
IGT, low HDL, and 
metabolic syndrome. 
Pediatric LT recipients 
have unique metabolic 
syndrome profiles and risk 
factors, and will require 











 Long-Term Renal 



























impairment in LT 
recipients. 
85 patients switched 




78 met the inclusion 
criteria. 
Within the first 6 weeks 
after switching, the 
covariable adjusted 
eGFR increased 5.6 
mL/min, but there were 
no further statistically 
noticeable changes in 




within the first 12 
months after drug 
conversion. 
Histologically proven 
graft rejection was 
observed in 4 patients 
(5.1%) after conversion. 
Conversion from CNI-
based to CNI-free, mTOR 
inhibitor-based 
immunosuppression after 
LT is safe and can result in 
significant renal recovery. 
CNI-free, mTOR 
inhibitor-based 
immunosuppression is a 
potential option for 
patients with 
contraindications for CNIs 
and for LT recipients with 
rapid reduction in kidney 


























protocol included a 
single dose of 
rituximab and total 
plasma exchange. 




or splenectomy was 
used for a certain 
time period, but 
these treatments 
were eventually 
discontinued due to 
adverse events. 
235 adult patients 
who underwent 
ABOi living donor 
liver transplantation 
(LDLT) at a single 
center between 
November 2008 and 
December 2013. 
3 cases (1.3%) of in-
hospital mortality. The 
cumulative 3-year graft 
and patient survival rates 
were 89.2% and 92.3%, 
respectively, and were 
comparable to those of 
the ABO-compatible 
group (n=1301). Despite 
promising survival 
outcomes, 17 patients 
(7.2%) experienced 
antibody-mediated 
rejection that manifested 
as diffuse intrahepatic 
biliary stricture; six 
cases required retrTL, 
and 3 patients died. 
 
The use of ABOi living 
liver donors is a very 
effective and safe method 
for expanding the donor 
pool in LDLT. DIHBS, an 
attenuated form of AMR, 
remains an unresolved 
problem despite the fairly 











Disease After Liver 
Transplantation: 
When, What, and 


















455 consecutive LT 
recipients from 
1999 to 2004 with 
an 8- to 12-year 
follow-up was 
performed. 
Tacrolimus use versus 
noncalcineurin-based 
immunosuppression 
(HR, 0.26; 95% CI, 
0.14-0.49; P < 0.001) 
was associated with 
reduced risk of CVD but 
not versus cyclosporine 
(HR, 0.67; 95% CI, 
0.30-1.49; P 5 0.322). 
CVD is common after LT. 
Independent of MS, more 
data are needed to identify 
nonconventional risk 
factors and biomarkers 
like serum TN. Curbing 
weight gain in the early 
months after transplant 
may impact MS and 














Comparison of Three 
Different 
Immunosuppressive 













efficacy and safety 
of standard IS 
regimens with the 
efficacy and safety 
of steroid-free IS 
regimen and 
induction IS 
regimen in Chinese 
liver transplantation 
recipients for HCC. 
329 patients who 
underwent LT from 
Jan 2008 -  Dec12. 
1) tacrolimus(29) 
and MMF (triple-
drug regimen group; 
n=57), 2) 
basiliximab, steroid, 
TAC and MMF (BS 
group; n=241), 3) 
Steroid-free; 
basiliximab, TAC 
and MMF (SF 
group; n=31) 
No significant 
differences in terms of 
patient, tumor-free and 
graft survival rates. The 
acute rejection rate and 
rejection time were 
equivalent in different 
groups. But compared 
with BS group, higher 
incidences of biliary 
complications (11.52% 
vs. 30.77%) and graft 
dysfunction (0.48% vs. 
13.64%) were observed 
in SF group.  
Steroid-free IS regimen 
has no clear advantages in 
comparison with standard 
IS regimens for liver 
transplant recipients with 
HCC and the postoperative 
complications should be 
treated with concentrated 
attention. Patient, tumor-
free and graft survival 
rates were equivalent 
among three IS regimens, 
higher incidences of 
complications were 
demonstrated in steroid-




































outcome and impact 
of the 
immunosuppressive 
therapy on NC 
development after 
LT 
We analysed 478 
LT in 440 patients, 
and 93 (19.5%) 
were followed by 
NCs 
The average LOS was 
longer in patients 
experiencing NCs. The 
1-, 3- and 5-year graft 
survival and patient 
survival were similar in 
patients with or without 
a NC. An everolimus-
based IS, 7.1% got NCs, 
vs. the 16.9% receiving 
a CNI. There was a 1-, 
3-, 5-year NC-free 
survival of 82%, 81% 
and 77.7% in patients 
receiving a CNI-based 
regimen and 95%, 94% 
and 93% in those not 
receiving a CNI-based 
regimen. 
In patients undergoing a 
LT and presenting with 
nonmodifiable risk factors 
for developing NCs, an IS 
regimen based on CNIs is 
likely to result in a higher 
rate of NCs compared to 
mTOR inhibitors. 
The average LOS was 
longer in patients 
experiencing NCs 
Multivariate analysis: 
independent risk factors 
for NC: a MELD score≥20 













 Analysis of adult 20-









data collected at 
a single center 








survivors 20 years 
post-LT, cause of 
death during the 
same period and 
risk factors of 
mortality. 
Between 1988 and 
1994, 132 patients 
received 151 
deceased-donors LT 
and 28 (21 %) 
survived more than 
20 years. 
Renal dysfunction was 
observed in 40 %, 
median eGFR among 
20-year survivors was 
64. 61% of 20-year 
survivors had arterial 
hypertension, 43 % 
dyslipidemia, 25 % de 
novo tumors and 21 % 
diabetes mellitus. 
Infections were the main 
cause of death during the 
1st year post-transplant 
(32 %) and between the 
1st and 5th year post-
transplant (25 %). After 
5th year from transplant, 
hepatitis C recurrence 
(22 %) became the first 
cause of death.  
Factors having an impact 
on long-term patient 
survival were HCC (p = 
0.049), pretransplant renal 
dysfunction (p = 0.043) 
and long warm ischemia 
(p = 0.016); furthermore, 
post-transplant factors 
were DIA (p = 0.001) and 
liver dysfunction (p = 
0.05) at 1 year. The results 
showed the effect of IS 
used during decades on 
long-term outcome in our 
LT patients in terms of 
morbidity (arterial 
hypertension, diabetes 
mellitus, dyslipidemia and 
renal dysfunction) and 













 Delayed Bottom-Up 
and Amended Simple 


















introduced as an 
alternative to twice-
daily formulations 
de novo. Dosing 
recommendations 
range between 0.1 
to 0.2 mg/kg BW/d. 
TacOD was given to 
101 patients 
undergoing primary 





received TacOD as 
de novo 
immunosuppressive 
agent were included 
in the analysis. 
A median of 9 mg/d of 
TacOD were necessary 
to establish the trough 
levels by day 10, which 
was then 5.4 ng/ml. 
Incidence of (AE); 
neurological AEs (n=3), 
were low. Efficacy 
failure (acute rejection) 
was low (4.9%). Renal 
function was stable and 
did not deteriorate under 
CNI treatment. 
This is the first report of 
bottom-up, amended, and 
simple dosing of TacOD 
in LT. The algorithm is 
feasible, safe, and 
efficient, avoiding trough 














 An analysis of 
tacrolimus-related 
complications in the 
first 30 days after 





Orthotopic LT has 
improved survival 







and avoid early 
complications are 
lacking. To 
correlate the dose 








2011 to May 2013, 
44 adult liver 
transplant recipients 
were included in the 
study 
5 cases ACR (11.37%), 
16 cases of infection 
(36.37%). The blood 
samples: significant 
correlation between the 
Tacrolimus blood level 
and the deterioration of 
glomerular filtration rate 
and serum creatinine. 
Patients with infections 
had a higher serum level 
of Tacrolimu. The dose 
and presence of rejection 
were significantly 
different (p=0.048) and 
the mean GFR was 
impaired in patients who 
underwent rejection 
compared with patients 
who did not. 
Blood Tacrolimus levels 
greater than 10 ng/ml were 
correlated with impaired 
renal function. Doses 
greater than 0.15 
mg/kg/day were associated 
with the prevention of 
acute cellular rejection but 











r Effect of delayed 
CNI-based 
immunosuppression 
with Advagraf on 
liver function after 
MELD-based LV 
(IMUTECT). 









Advagraf on the 
reate of infectious 
complications, graft 
and renal function 
after LT. 
50 patients with de 
novo low-dose 
standard Advagraf-
based IS consisting 
of Advagraf, MMF 
and corticosteroids 
after LT. 2 group 
with 25 patients. 
Low-dose Advagraf-
based IS regime would 
decreas both the 
infection rate (CMV-
reactivation, wound 
infection, Urinary tract 
infections, and 
pneumonia) and 
associated negative side 
effects of a CNI-based 
IS strategy, especially in 
patients with renal 
impairment.  
Prolonged-release, low-
dose Advagraf is predicted 
to better protect patients 
form CNI side effects 
when compared to 
standard IS regime, while 
simultaneously 
maintaining graft function 
and not elevating the rate 


















in De Novo Liver 
Transplant 
Recipients: 1-Year 
Experience From a 
Phase II Randomized 
Study. 









phase II clinical 




efficacy and safety 
of belatacept in 
adult recipients of 
first LTs from a 
deceased donor. To 
identify an optimal 
IS regimen in LT 
recipients, three 
belatacept regimens 
were studied and 
compared with two 











(N=260) to one of 
the following IS 
regimens: (i) 
Basiliximab+ 
belatacept high dose 
[HD] + MMF, (ii) 
belatacept 
HD+MMF, (iii) 
belatacept low dose 
[LD]+MMF, 
(iv)Tacrolimus + 




The proportion of 
patients who met the 
primary end point 
(composite of acute 
rejection, graft loss, 
death by month 6) was 
higher in the belatacept 
groups (42–48%) versus 
tacrolimus groups (15–
38%), with the highest 
number of deaths and 
grafts losses in the 
belatacept LD group. 
Distinguishing the 
contribution of belatacept 
alone or an interaction 
between belatacept and 
such factors in the context 
of this phase II study is not 
feasible. An additional 
limitation of the study 
includes the open-label 











i Incidence of anti-











The incidence of de 
novo DSAs using 












different IS regimes. 
56 LT peatients 
converted from 
CNIs to mTOR 
inhibitors and were 
included in the 
study.  
After conversion from 
CNIs to an mTOR 
inhibitor-based CNI-free 
IS, three of the 56 
patients developed de 
novo DSAs (6.5%), a 
biopsy-proven acute-
rejection episode 
occurred in four of the 
56 patients (7%), and a 
biopsyproven or 
suspected acute-rejection 
occurred in 6/ 56 
patients (10.7%). 
In maintenance LT, the 
incidence of de novo 
DSAs seems to be 
relatively infrequent and 
similar between patients 
receiving mTOR-based 
CNI-free IS and CNI 
based IS, after late 
conversion to mTOR 
based treatment, usually as 
















Hepatitis C in the 
Japanese Liver 
Transplant Patients 




Telaprevir (TVR) is 
a protease inhibitor 
used in combination 
with pegylated 
interferon alfa-2b 
and ribavirin for 
hepatitis C, and 
TVR strongly 
inhibits CYP3A4 
and CYP3A5. We 
reported successful 




hepatitis C during 
receiving is 
therapy. 
4 cases.  
The clinical 
characteristics of the 
patients in this study 
are summarized in 
Table 1. All patients 
showed a recurrence 
of HCV genotype 
1b after liver 
transplantation. The 
median (range) of 
duration between 
liver transplantation 
and initiation of 
TVR treatment was 
21. 
we found the rapid 
elimination of inhibitory 
effect of TVR on the 
disposition of 
cyclospirne in the all 
four cases and therefore, 
rapid increase in the 
dosage of cyclosporine 
would be required 
immediately after the 
end of TVR 
administration. 
These results suggest that 
frequent measurement of 
cyclosporine levels was 
important for successful 
TVR triple therapy and 
prevention of rejection. 
Treat patients with 
recurrence of hepatitis C 
after LT by TVR therapy 
to avoid liver graft 
rejection. Controlling the 
drug interaction between 
TVR and cyclosporine was 
the most important aspect 
to achieving both 
treatment of hepatitis C 


































381 adult patients in 
the Japanese 









After adjustment for era 
effects in the 
multivariate analysis, 
only absence of 
rituximab prophylaxis 
was a significant risk 
factor for AMR, and 
there were no significant 
risk factors for survival. 
Rituximab prophylaxis 
sign. decreased the 
incidence of AMR, 
especially hepatic 
necrosis. In the 
rituximab group, other B 
cell desensitization 
therapies had no add-on 
effects 
Multiple or large 
rituximab doses 
significantly increased the 
incidence of infection, and 
early administration had 
no advantage. In 
conclusion, outcomes in 
adult ABO-I LDLT have 
significantly improved in 
the latest era coincident 











 Incidence and Long-














risks after liver 
transplantation (LT) 
with implications 




up (mean follow-up 
5 7.25 years) at our 
outpatient clinic up 
to December 31, 
2011.  
The cancer incidence 
rates for the LT 
recipients were almost 
twice as high as those 




surveillance is proposed. 
Tumor treatment 
performed according to 
accepted guidelines 
appears adequate. 
Mycophenolate may lead 
to lower long-term risks 














 The evolution of liver 
transplantation 
during 3 decades: 
Analysis of 5347 
consecutive liver 
transplants at a 
single center. 
Annals of Surgery, 
2013 














of the model for 
end-stage liver 
disease (MELD) in 
2002 represented a 
fundamental shift in 
liver donor 
allocation to 







OLTs performed in 








morbidity before (n 




Overall, 1-, 5-, 10-, and 
20-year patient and graft 
survival estimates were 
82%, 70%, 63%, 52%, 
and 73%, 61%, 54%, 
43%, respectively. Of 17 
recipient and donor 
variables, era of 
transplantation, etiology 
of liver disease, recipient 
and donorage, prior LT, 
MELD score, 
hospitalization at time of 
OLT, and cold and warm 
ischemia time were 
independent predictors 
of survival. 
We present the world’s 
largest reported single-
institution experience with 
OLT. Despite increasing 
acuity in post-MELD era 
recipients, patient and 
graft survival continues to 
improve, justifying the 












 Impact of 
cyclosporine versus 
tacrolimus on the 
incidence of de novo 
malignancy following 
liver transplantation: 
a single center 







malignancies are a 
major cause of late 
death after liver 
transplantation. 
Aim of the present 
study was to 
determine whether 








malignancies in 609 
liver transplant 
recipients at Munich 
Transplant Centre 




revealed recipient age 
[hazards ratio (HR) 
1.06], male gender (HR 
1.73), and tacrolimus-
based IS (HR 2.06) as 
significant risk factors 
a tacrolimus-based IS 
should be discussed 
especially in older male 
patients. Whether reducing 
tacrolimus target levels 
may reduce the risk for de 
novo malignancies has yet 

























efficacy and safety 
of using 
basiliximab in place 
of a corticosteroid 
for IS following LT 
for HCC. 
178 Chinese 








The median overall and 
disease free survival was 
similar between 
basiliximab (50.8 
months and 19.6 months, 
respectively) and steroid 
treated patients (64.2 
months and 23.8 months, 
respectively). The 5-year 
overall survival and 
disease free survival 
rates was also similar 
between the basiliximab 
and steroid.  
These findings provide 
further evidence of the 
negative impact of steroids 
as a part of 
immunosuppression 
therapy following liver 
transplantation for HCC. 
Patients w. Milan criteria 
were basiliximab 
associated with greater 5-
year overall survival rate 



















Experience of 313 
Consecutive Cases. 




















term outcome was 
studied and a 







were performed in 
313 patients (09/88–
12/92). 
Patient and graft survival 
at 1, 10, 20 years were 
88.4%, 72.7%, 52.5% 
and 83.7%, 64.7% and 
46.6%, respectively. 
Recurrent disease 
21.3%, infection 20.6%, 
de novo malignancy 
(19.9%) common causes 
of death. Prevalence of 
HTN 57.3–85.2%,, 
MIRF 41.8–55.2%, and 
HBMI 33.2–45% 
increased true follow up, 
while prevalence of 
HLIP (78.0–47.6%, 
declined. 
Recurrent disease (21.3%), 
infection (20.6%) and de 
novo malignancy (19.9%) 
were the most common 
causes of death. 
LT has conquered many 
barriers to achieve these 
outstanding long-term 
results. However, much 
work is needed to combat 














l Cyclosporine and 
Tacrolimus Have 
Inhibitory Effects on 
Toll-Like Receptor 










(TLRs) play a key 
role in 
transplantation 
biology. The effect 
of IS on TLR 





(PBMCs) from 113 




ligands for 24 hours. 
PBMCs from 5 
healthy controls 






PBMCs from patients on 
CNI after LT produced 
less IL-6 and TNFa in 
response to TLR2 
stimulation, compared 
with healthy controls. 
Both CD56bright and 
CD56dim NK cells from 
patients on CNIIN also 
produced less IFNg with 
TLR7/8 stimulation 
compared with healthy 
controls. Similar 
findings in healthy 
PBMCs cultured with 
CYA. 
Patients on calcineurin 
inhibitors had impaired 
inflammatory cytokine 
production in response to 
TLR2, TLR4, and TLR7/8 
stimulation compared 
comparison with healthy 
controls. TAC and CYA 
appear to have different 
effects on TLR signaling. 
Impaired TLR function 
has repercussions for risk 
of infection, graft 
rejection, and disease 
recurrence after LT, and 
the different IS profiles of 
CYA and TAC may guide 











 Trial of Complete 
Weaning From 
Immunosuppression 



















function tests and 
without active viral 
hepatitis or 
autoimmune disease 
who presented with 
side effects of 
immunosuppression 
or a high risk of de 
novo malignancies 
were selected. 24 
patients fulfilled the 
criteria 
Median tolerance of 14 
months. Tolerant 
patients had a longer 
median interval between 
transplantation and 
inclusion in the study 
(156 for tolerant patients 
versus 71 months for 
nontolerant patients, 
P50.003) and a lower 
median SI (7.49 for 
tolerant patients versus 
41.73 for nontolerant 
patients. 
A high proportion of select 
LT recipients can reach 
tolerance over the long 
term. Two simple basal 
variables—the time from 
transplantation and the 





























mofetil (MMF) and 
sirolimus (SRL) 








LT from July 05 - 
07 who were 
maintained on 
MMF/CNI were 
randomized 4 to 12 
weeks after LT to 
receive MMF/ SRL 
(n=148) or continue 
MMF/ CNI (n=145) 




associated with a greater 
renal function 
improvement from 
baseline with a mean % 
change in GFR. The 
composite endpoint 
demonstrated the 
noninferiority of MMF/ 
SRL vs. MMF/CNI. The 
incidence of BPAR was 
significantly greater with 
MMF/SRL (12.2%) vs. 
MMF/CNI. Graft loss 
(including death) 
occurred in 3.4% of the 
MMF/SRL-treated 
patients and in 8.3% of 
the MMF/CNI-treated. 
Malignancy-related deaths 
were less frequent with 
MMF/SRL. Adverse 
events caused withdrawal 
for 34.2% of the 
MMF/SRL-treated 
patients and for 24.1% of 
the MMF/CNI-treated 
patients (P50.06). The use 
of MMF/SRL is an option 
for liver transplant 
recipients who can benefit 
from improved renal 
function but is associated 
with an increased risk of 





















Ribavirin to Treat 
Hepatitis C Genotype 





review,             
at Mayo Clinic 
in Jacksonville, 
FL; at Mayo 
Clinic in 
Scottsdale, AZ; 
and at Mayo 
Clinic in 
Rochester, MN. 
The safety, efficacy, 
and effect on IS 
levels of telaprevir 
(TVR) or 




ribavirin (RBV) in 
recipients of  with 
HCV genotype 1 
have not been 
defined 
60 pat. started triple 
antiviral treatment, 
were followed for 
66 weeks 30 of the 
35 patients treated 
with TVR (86%) got 
undetectable HCV 
RNA levels after an 
average of 6 weeks, 
whereas 12 patients 
(48%) in the BOC-
treated group got 
undetectable HCV 
RNA levels after a 
mean of 11 weeks. 
Cytopenias complicated 
both regimens; all 
patients required dose 
reductions of PEG-IFN 
and/or RBV or the 
administration of 
hematological growth 
factors. One death 
occurred in each group 
on triple antiviral 
treatment 
TVR or BOC combined 
with PEG-IFN/RBV 
achieved ontreatment 
virological response rates 
of approximately 50% to 
60% in patients with 
recurrent HCV after LT, 













 The imbalance of T 
helper 17/ regulatory 
T cells and memory B 
cells during the early 
post-transplantation 
period in peripheral 










Serial changes of T 
cells and B cells in 
living donor liver 
transplantation 
(LDLT) recipients 





From June 2010 to 




Serial monitoring of 
immunological profiles 
showed no significant 
suppression of Th1, Th2, 
Th17, mature B or 
memory B cells, 
whereas frequencies of 
Treg cells significantly 
decreased. Interleukin-
17 production by central 
and effector memory 
cells was not suppressed 
during the early post-
operative period. The 
continuous production of 
interleukin-17 by the 
memory T cells may 
contribute to the 
persistence of Th17cells. 
current IS maintained the 
effector T or memory B 
cells during the early post-
transplantation period but 
significantly suppressed 
Treg cells. Serial immune 
monitoring may suggest 
clues for optimal or 
individualized 
immunosuppression 
during the early post-
























consequences of IS 
will have a broad 
impact on immune 





adaptive and innate 
alloresponses to 
immunosenescence 
may justify both 
reduced and adapted 
IS maintenance 
therapy in old 
recipients. But, at 
the same time, may 
require a potent 
early IS. 




reserves while at the 
same time, an 
augmented 
immunogenicity of older 
organs has been 
reported. 
Older recipients mount 
compromised alloimmune 
responses in experimental 
and clinical studies. Both, 
advanced donor and 
advanced recipient age are 
thus risk factors for 
inferior transplant 
outcome and require 
adapted organ allocation 




















Ann Saudi Med, 
2012 
Retrospective 
study of patients 
referred to LT 
center between 
Apr 2001 - Jan 
2010. Collected 






The recipients of 
LT are subjected to 
lifelong IS with its 
many drawbacks. 








with de novo 
malignancies 
encountered after 
both deceased and 
living donor LT 
248 LT procedures 




developed de novo 
post-LT 
malignancies. 
De novo malignancies 
included PTLD in 5 
patients who were all 
EBV positive, and who 
were treated successfully 
with anti-CD20 
monoclonal antibody 
therapy, reduction of IS, 
and control of EBV 
activity; urinary bladder 
cancer in 1 patient, died 
of bone and lung 
metastasis within 1 year 
of diagnosis; 
endometrial carcinoma 
in 1 patient, and Kaposi 
sarcoma in 1 patient 
survived. 
EBV-associated PTLD is 
the most frequently 
encountered de novo 
malignancy after LT and is 
easily treatable by 
chemotherapy and 











a Limiting Hepatitis C 





American Society of 
Transplantation, 2011 
Cohort study. Hepatitis C virus 
(HCV) causes 
progressive liver 
fibrosis in LT 
recipients and is the 




of sirolimus are 
seen in animal 
models but have not 
been described in 
liver transplant 
recipients. 
We reviewed 1274 
liver recipients from 
2002 to 2010 and 
identified a cohort 
of HCV recipients 
exposed to sirolimus 
as primary IS (SRL 
Cohort) and an 
HCV Control Group  
(71) of recipients 
who had never 
received sirolimus. 
Yearly protocol biopsies 
were done recording 
fibrosis stage 
(METAVIR score) with 
biopsy compliance of 
>80% at both year 1 and 
2. In an intent-to-treat 
analysis, the SRL Cohort 
had significantly less 
advanced fibrosis (stage 
≥2) compared to the 
HCV Control Group at 
year one (15.3% vs. 
36.2%) and year two 
(30.1% vs. 50.5%).  
This is the first study 
among liver transplant 
recipients with recurrent 
HCV to describe the 
positive impact of 
sirolimus in respect of 
reduced fibrosis extent and 



























Risk factors and 
clinical outcome of 
ECIIN remain 





the incidence, risk 
factors, and 
outcome of ECIIN 
after LT. 
158 patients that 
underwent LT in a 
2-year period and 
received IS with 
calcineurin 
inhibitors (CNI) and 
prednisone. 
ECIIN was considered 
when moderate/severe 
neurological events 
occurred within 4 weeks 
after LT and improved 
after modification of 
CNI. Demographic and 
clinical variables were 
analyzed as risk factors. 
18% of patients 
developed ECIIN and 
the remaining 130 
patients were controls. 
ECIIN group: frequent 
Acute graft rejection and 
infections, and longer 
length of stay. 
pre-LT hepatic 
encephalopathy, surgical 
time >7 h, and post-LT 
hyponatremia are risk 
factors for ECIIN. Clinical 
complications and a longer 
hospital stay are associated 



















A registry study 








are not well known, 
especially for 
hepatitis C (HCV) 
16 898 adult 
primary LT patients 
who received ATG 
alone (n = 452), 
ATG and steroids 
(ATG + S) (n = 
1758), daclizumab 
alone (n = 683), or 
steroid alone (n = 14 
005), listed as 
induction IS. 
Patients with HCV, 
ATG + S had sign. 
inferior graft survival 
compared with 
daclizumab + S. The 
Cox proportional 
hazards model also 
showed that ATG + S 
was a marginal risk 
factor for graft failure. 
For patients with all the 
liver diseases, graft and 




ATG induction appeared 
to be preferentially used in 
patients with renal 
dysfunction, with 
improvement in renal 
function after LT. ATG 
induction can be used for 
patients with renal 
dysfunction in non-HCV 
diseases. Daclizumab 
induction achieved 
satisfactory short-term and 
long-term outcomes of LT 
in all the liver diseases 





















Nonadherence to IS 
carries a risk of 
graft rejection and 







after LT) may be 
associated with 
other complications 




Patients have been 
split into 2 age 
groups (adults and 
children/adoles-
cents) because the 
scale of the problem 
and the potential 
risk factors differ in 
the 2 groups. 
At Padua University 
Hospital in Italy: 
103 LT patients got 
evaluated at a mean 
of 85.1 6 5.5 months 
after transplantation. 
46% of the patients 
reported nonadherent 
behaviour related to the 
intake of IS drugs. 
Nonadherence patterns: 
26.2% taking their 
medication late, 18.4% 
missed a dose, 2.9% 
changed their dosage 
without consulting their 
doctors. 25% smoking, 
19.4% alcohol intake, 
8.7% smoking+drinking. 
11.7% were taking other 
nonIS not prescribed by 
their physicians, 3.9% 
not attending outpatient 
appointments regularly, 
2.9% not turning up for 
the blood tests. 
The alarming picture 
emerging from the studies 
analyzed in this review is 
that poor adherence is an 
issue for nearly 1/2 LT 
patients, and this coincides 
with substantial increases 
in the rates of LAR, graft 
loss, and death. Patients 
and health care providers 
dealing with LT patients 
need to be properly trained 
to address nonadherence 
and be able to use all 
available means to 
improve their patients’ 














 Increased Incidence 
of Early De Novo 
Cancer in Liver Graft 
Recipients Treated 
with Cyclosporine: 
An Association with 






The goal of this 
study was to 
determine the risk 
factors for de novo 
cancer after liver 
transplantation 
(LTx) 




13.0% of recipients 
developed de novo 
malignancy. 
Cumulative incidence of 
de novo cancer at 1, 5, 
10, and 15 years: 2.9%, 
0.9%, 10.5%, 1.8%, 
19.4%, 3.0%, 33.6%, 
6.8%. Univariate risk 
factors for de novo 
cancer; CsA treatment, 
time period of LTx, age. 
Only CsA treatment 
emerged as an 
independent risk factor 
for de novo cancer, 
which attributed to more 
aggressive cancer types.  
Compared to tacrolimus 
treatment, CsA treatment 
with C2 monitoring or in 
younger patients of <50 
years is associated with a 
higher early de novo 
cancer risk after LTx. The 
standardized incidence 
ratio of malignancy in LTx 
patients compared to the 


















care following liver. 
Journal of American 
Information 
Association, 2010.  
 
A retrospective 
















following LT, if not 
managed well, can 
lead to increased 
drug toxicity or 
rejection episodes. 
We investigated 
whether use of an 
automated clinical 
management 











using a paper 
charting system. 










that system.  
Multivariable logistic 
regression analysis 
showed the automated 
system was significantly 
associated with fewer 
rejection episodes and 
fewer tacrolimus toxicity 
events. Formal cost-
effectiveness analysis of 
the nurses’ salaries for 1 
year showed the 
automated system cost 
US$197 per patient and 
the paper system cost 
US$1703 per patient. 
The automated system 
improved quality of life 
years. 
Use of an automated 
clinical management 
system for outpatient IS 
management for LT 
patients has resulted in a 
decrease in both 
tacrolimus toxicity and 


















disorder in a liver 
transplant recipient. 
European Society for 
Organ 
Transplantation, 2010 





the major cause of 
malignancy-related 
mortality after solid 
OT. Primary or 
reactivated EBV 
and CMV infection, 
treatment with T-
cell antibodies, and 
especially the 
amount of overall 
IS are known risk 
factors. 
The first LT 
recipient with 
complete remission 
of a malignant 
monoclonal B-cell 
lymphoma after 
sirolimus add-on to 
a triple IS regimen 
without CNI 
withdrawal: A 20 
year old, LT in 1998 




because of sirolimus 
add-on treatment was 
achieved within 3 
months. Given that 
sirolimus induced B-cell 
growth inhibition is 
reversed by the addition 
of tacrolimus in vitro, 
this was an unexpected 
clinical course. 
Complete withdrawal of 
CNIs is still 
recommended, but as 
demonstrated, a slow taper 
is possible and preferable 
to avoid rejection 
episodes. In addition, in 
patients with limited 
PTLD, start of 
chemotherapy may be 
delayed under strict 
surveillance to await 

















 A therapeutic 
exploratory study to 
determine the 
















IS with CNI 
increases the risk of 
renal dysfunction 
after OLT. This 
study protocol was 
designed to assess 




novo IS after LT. 
29 liver transplant 
patients was 
designed to assess 
the safety and 
efficacy of de-novo 






Reducing or delaying 
CNI is safe and reduces 
renal impairment. But it 
is not known if complete 
abdication of CNI may 
increase the risk of 
rejection. 
This study represents an 
intermediate element of 
the research chain. If the 
data of the phase II study 
corroborates safety of de-
novo CNI-free IS regimen 
this should be confirmed 















 Primary Biliary 



















(rPBC). The impact 
of IS and HLA 
mismatches on 
rPBC is unclear. 
103 consecutive 
PBC patients who 
underwent LT 
(follow-up > 10 
months) with serial 
protocol biopsies. IS 
was cyclosporine-
based in 38 (10 on 
monotherapy), 
tacrolimus-based in 
62 (19 on mono 
therapy). Steroids 
were discontinued 
in all but 7. 
Azathioprine was 
part of the initial IS 
in 70, 26 
discontinued it, and 
33 never exposed. 
rPBC was associated 
independently with 
nonuse/discontinuation 
of azathioprine. The 
mean time to rPBC was 
74 months with 
azathioprine, 43 months 
when AZA was 
discontinued, and 31 
months if no 
azathioprine was used. 
Cyclosporine or 
tacrolimus alone had no 
impact on rPBC, but 
cyclosporine with 
azathioprine was 
protective for rPBC in 
comparison with 
tacrolimus/azathioprine 
(0/18 versus 7/25) 
rPBC was not affected by 
HLA mismatches. 
Azathioprine use in PBC 
patients who underwent 
LT was associated with 
less disease recurrence and 
a longer time to rPBC. 
Tacrolimus or 
cyclosporine individually 
had no effect, but 
cyclosporine and 
azathioprine in 
combination resulted in 






















Postal survey As long-term 







which group of 
providers should be 
managing liver 








practice patterns in 




response rate was 
68.2%. 
Hepatologists felt that 
metabolic complications 
were common, but few 




diabetes mellitus (8.8%), 
dyslipidemia (11.1%), 
bone disease (12.8%) 
were well controlled. 
The majority of 
hepatologists indicated 
that ideally PCPs should 
be managing recipients’ 
hypertension, diabetes 
mellitus, dyslipidemia, 
and bone disease. 
Metabolic complications 
are perceived to be 
common but not well 
controlled post-transplant, 
and most hepatologists 
feel that PCPs should take 
a more active role in the 




























literature study / 
review study.  
No official 








The data presented 
are based on formal 
review and analysis 
of published 
literature in the field 
and the clinical 
experience of the 
authors. 
These guidelines address 
drug interactions and 






and productivity in the 
workforce, issues 
specific to pregnancy 
and sexual function, and 
pediatric patient 
concerns. 
These guidelines are 
intended to provide a 
bridge between transplant 
centers and primary care 
physicians in the long-
term management of the 













t Renal Impairment 
After Liver 
Transplantation - A 
Pilot trial of 
calcineurin inhibitor-
free vs. calcineurin 
inhibitor sparing 
immunosuppression 
in patients with 
mildly impaired renal 
function after liver 
transplantation. 
European Journal of 
Medical Research, 
2009 
A pilot trial, 
RCT with only 
21 patients.  
Chronic kidney 
disease is frewuent 
in patients after 
OLT and has 
impact on survival. 
Patiensts receiving 
CNI are at 





concomitant use of 
MMF has been 
shown to improve 
renal function.  
21 patients were 
randomized either to 
exchange CNI for 
10 mg prednisone or 
to receive CNI at 
25% of the initial 
dose each in 
combination with 
1000 mg MMF b.i.d 
At mount 12 mean SCr 
and GFR improved in 
group 2 but remained 
unchanged in group 1. 
Main side effects were 
GI-symptoms (14.3%) 
and infections (4.8%). 
Two biopsy proven, 
steroid-responsive 
rejections occurred . In 
group 1 mean diastolic 
BP increased by 11 ± 22 
mmHg. 
 
Reduced dose CNI in 
combination with MMF 
but not CNI-free-IS leads 
to improvement of GFR in 
patients with moderately 
elevated SCr levels after 
OLT. Addition of steroids 
resulted in increased 
diastolic blood pressure 
presumably 
counterbalancing the 
benefits of CNI 



























31 adult LT 
recipients. All 




(SRL) (n = 10) or 
without SRL 
(tacrolimus (TAC) 
(n = 10), 
mycophenolate 
mofetil (MMF) (n = 
11)) for >6 months. 
The SRL monotherapy 
group had significantly 
higher percentages of 
CD4 + CD25high + 
Foxp3+ T cells 
compared with the non-
SRL group. The SRL 
effect was even higher in 
a subset with prior AL 
induction and no prior 
HCV or rejection 
compared with all other 




compared with non-TAC 
patients.  
IS monotherapy provides 
an opportunity to 
investigate regulatory 
roles of individual agents. 
SRL maintenance and 
prior AL induction in 
subsets of patients 
appeared to show a 
regulatory T cell 
immunophenotype. 
However, TAC patients 
may have other regulatory 
characteristics, supporting 
the need for larger, 











t Minimization of 






Because of the 
markedly improved 
short-term results of 
LT and persistently 






be focused on 
minimizing IS 
therapy as much as 
possible. 
Liver transplanted 





responsible for a 
substantial post-LT 
morbidity and mortality, 
hence, minimization of 
its use is of utmost 
importance to improve 
the quality of life of the 
successfully transplanted 
liver recipient. 
LT can be performed 
safely with steroid-
minimal IS without 
compromising graft and 
patient survival. The 
tendency in clinical 
practice is to move more 
and more from steroid 











 Impact of 
Immunosuppression 
Without Steroids on 
Rejection and 
Hepatitis C Virus 
Evolution After Liver 
Transplantation: 








The purpose of this 
study was to 
evaluate the 
influence of a 
steroid-free 
immunosuppression 
on hepatitis C virus 
(HCV) recurrence 
198 LT patients 
were randomized to 




group) or without 
prednisone (NoSt-
group). The group 
of 89 HCV-infected 
patients got biopsies 
for 2 years after LT. 
This group of HCV 
patients are the 
patients evaluated in 
the present study. 
The rejection rate was 
19% (St: 21% vs. NoSt: 
17%). Patients in the St 
group had more bacterial 
infections (59% vs 38%) 
97% of all patients had 
histological HCV 
recurrence. The % of 
accumulated biopsies 
with gr. 4 portal 
inflammation at 6 
months, 1 year, 2 years 
were, 23%, 49%, and 
49% in the NoSt group, 
vs. 33%, 55%, and 69% 
in the St group. For 
grade 3/4 fibrosis at 6 m, 
1 y, 2 y were 0%, 8%, 
and 22% for the NoSt 
group, vs. 8%, 19%, and 
31% for the St group. 
Immunosuppression 
without steroids in HCV 
patients is safe, reduces 
bacterial infections and 
metabolic complications, 
and improves histological 
















quality of life in adult 
transplant recipients 
more than 15 years 







rising survival rates 
following OLT 
health-related 






HRQOL in 104 
adult liver transplant 
recipients surviving 
more than 15 years 
after OLT was 
assessed using the 
German Version of 
the 36-Item Health 
Survey (SF-36). 
LT recipients surviving 
>15 years OLT scored 
lower in all categories; a 
poor HRQOL vs. the 
German ref. pop. A 
statistical sign. was 
reached in almost all SF-
36 with the exceptions 
of mental health and 
bodily pain, where our 
study pop. = ref.pop. Job 
rehab. after OLT good 
effect on HRQOL. 
Returning to their job 
during the first year after 
OLT sign. higher of 
physical functioning, 
role phys. 
Marital status and the IS 
used didn’t affect HRQOL 
as there was no statistical 
significance reached in any 
of the comparisons 
performed. > 15 years 
after OLT, long-term 
survivors present a poor 
HRQOL comparable to the 
reference population. 
Occupational rehab. was 












 Nifedipine Versus 
Carvedilol in the 













The aim of this 
study was to 
compare nifedipine 
and carvedilol in 




The study included 
50 patients who 
developed arterial 
hypertension after 
OLT. 25 patients 
received nifedipine 
(group A), and 25 
received carvedilol 
(group B) 
All were similar for 
baseline conditions. At 
end of study, patients 
intolerant to mono-
therapy were 48% of gr. 
A, 12.5% of gr. B. Full 
responders were 20% of 
gr. A and 33% of gr. B. 
The addition of ramipril 
normalized BP in 19% 
of partial responders to 
m-therapy (75% in 
partial responders to 
nifedipine, 30% in 
partial responders to 
carvedilol) 
In responders to either 
monotherapy or combined 
therapy, there was a 
significant improvement of 
renal function. In 
responders to carvedilol, 
but not in responders to 
nifedipine, the daily dose 
of tacrolimus at 1 year 
should be reduced to 50% 
compared to the baseline 
dose to maintain the blood 





























A 1-yr interim 




This study evaluate 
the effect of 
corticosteroid-free 














MMF (Arm 3; n= 
153). 
At 1 yr, 64.1%, 63.4%, 
and 69.4% of patients 
achieved the composite 
primary endpoint of 
freedom from rejection, 
freedom from HCV 
recurrence, and freedom 
from treatment failure, 
respectively. Excellent 
patient and graft survival 
did not differ sign. 
among treatment arms. 
Freedom from HCV 
recurrence at 1 yr was 
6.2%, 6.1%, and 4.3% in 
Arms 1, 2, 3. Freedom 
from rejection was sign. 
higher in Arm 3 vs. 1.  
these results suggest that a 
corticosteroid-free 
regimen of tacrolimus and 
MMF following 
daclizumab induction is 
safe and effective in 










a B-Cell Surface 









Cohort study  The effectiveness of 
rituximab has been 
reported in ABO 
blood gr ABO-I LT, 
but the protocol is 
not yet established. 
The impact of 
timing of rituximab 
proph. and the 
humoral immune 
response of patients 
undergoing ABO-I 
LDLT, focus on 
clinic-pathologyical 
findings and the B-
cell subset. 
30 adult patients 





ABO-I LDLT. A 
total of 17 patients 
were treated only 
with HAI (no 
prophylaxis), and 13 
were treated with 
rituximab 
prophylaxis. 
The mortality of the 30 




was 33% and the main 
cause of death was 
sepsis. Early rituximab 
prophylaxis sign. Deple-
ted B cells and memory 
B cells in the spleen but 
not in lymph nodes. BC  
and memory BC 
increased and memory 
BC became dominant 
during antibody-
mediated rejection. 
Early prophylaxis with 
rituximab depletes B cells, 
including memory B cells, 
in the spleen and is 
associated with a trend 
toward lower humoral 
rejection rates and lower 
peak immunoglobulin 
























Surveillance to 3 
Years 




The 1-year results 
of the tacrolimus vs 
microemulsified 
cyclosporin (TMC) 
study found a 
benefit with 
tacrolimus IS after 
primary LT in 
adults with respect 
to freedom from 
graft loss and 
immunological 
failure. This is 







first liver transplant 
in any of the eight 
centers in the United 
Kingdom or 
Republic of Ireland. 
596 patients (298 in 
each group) 
However, freedom from 
death or reLT no longer 
achieves statistical sign. 
A total of 62.1% of 
patients randomized to 
tacrolimus were alive at 
3 years with their 
original graft and still on 
their allocated study 
medication, as compared 
with only 41.6%in the 
cyclosporin limb. 
No difference was 
detected between 
tacrolimus and cyclosporin 
in hepatitis-C-positive 
patients with the available 
data. The TMC study 
confirms after 3 years of 
follow-up the benefits of 
tacrolimus-based IS over 















Living Donor Liver 
Transplantation and 





A 3 patient 
study protocol.  
Long-term results 
of LT are still 
limited by serious 
side effects of IS 
drugs. A major 
issue, therefore, is 




minimization of IS 
therapy after LT. 
Report on 3 patients 
prospectively 
enrolled in an 
original protocol 
designed to promote 




high doses of 
antithymocyte 
globulin followed 
by injection of 
donor-derived stem 
cells. 
In 2 patients, early IS 
withdrawal was possible, 
without subsequent graft 
deterioration. In these 2 
cases, in vitro studies 
showed indices of 
immunological tolerance 
as assessed by specific 
hyporesponsiveness to 
donor alloantigens in 
mixed lymphocytes 
culture. In the third 
patient, acute rejection 
rapidly occurred after 
discontinuation of IS, 
and minimal IS has to be 
maintained during long-
term followup.  
these clinical observations 
demonstrated that, despite 
the absence of 
macrochimerism, donor 
stem cells infusion 
combined with recipient 
conditioning may allow 
early IS withdrawal or 




















tacrolimus to prevent 












related side effects 
in liver transplant 
recipients although 
their efficacy is 
very variable. 






At 6 months, the acute 
rejection rate was 9.8%, 
and patient and graft 
survival rates were 96% 
and 95%. Acute 
rejection rates were for 
HCV+ patients (8.6%) 
and HCV- patients 
(10.4%). Infections in 
22% of patients. Post-
transplantation HT and 
DIA developed in 37% 
and 14% of patients, 
during the study period, 
but were markedly less 
frequent (8% and 6%) at 
6 months. Hypercholest-
erolemia in only 2%. 
The steroid-free IS 
regimen of daclizumab, 
MMF, and tacrolimus 
effectively prevents acute 










i ABO-Mismatch Adult 











with 5 patients 










5 recipients (mean 
age of 47 +/- 14 yr) 
undergoing ABO-I 
LDLT were 
included in this 
protocol. 
Persisting low HA titers 
were observed over 
time. No sepsis nor 
cytomegalovirus 
infection episodes were 
recorded. ACR occurred 
in 1 recipient responding 
to steroid pulse therapy. 
Two grafts were lost in 2 
patients due to technical 
failure during the first 
postoperative month. 
ASI using Glycosorb 
ABO, quadruple IS 
including DAC and MMF 
provide high efficiency to 
lower HA titers over time, 
avoiding the need for 
splenectomy. ABO-I 
LDLT can be performed 















r Conversion From 
Tacrolimus to 










clinical outcomes of 
LT patients who 
experienced DM on 
tacrolimus-based 




25 patients were 
included after a 
median delay of 54 
months after LT, 51 
years (range 30-69). 
There were 11 
patients with 
insulin-treated DM 
(ITDM), 14 patients 
with noninsulintre-
ated DM (NITDM), 
and the glycemic 
control was poor 
52% of patients. 
After a median follow-
up of 20 month safter 
conversion, there were 
four patients with 
ITDM, 17 patients with 
NITDM, and four 
patients without DM, 
and the glycemic control 
was poor in 3/25 patients 
(12%). Four patients 
returned to tacrolimus 
because of arterial 
hypertension or 
digestive side-effects. 
The results suggest that 
conversion from 
tacrolimus to cyclosporine 
in stable LT patients with 
DM is well tolerated and 










 A New Side Effect of 
Immunosuppression: 









Little is known 
about hearing 
impairment in 
patients after LT. 
Evaluate hearing 
impairment in 
patients after OLT 
A questionnaire was 
sent to 695 adult 
patients after OLT 
to assess 
characteristics and 
course of auditory 
impairment. Risk 
factors such as 







analyzed in detail. 
The questionnaire 
was completed by 
521 patients (75%) 
Hearing impairment was 
reported by 35%. A total 
of 8% suffered from 
hearing abnormalities 
prior to OLT. There 
maining 141 patients 
(27%) developed 
hearing impairment after 
LT. Main problems were 
hearing loss (52%), 
tinnitus (38%), and 
otalgia (30%). There 
was no association of 
post-OLT hearing 
disorders with age or 
known risk factors. In 
43% of patients, onset of 
hearing impairment was 
within 2 yr post-OLT. 
subjective hearing 
impairment is frequent in 
patients after OLT and 
contributes to post-OLT 
morbidity. Calcineurin 
inhibitor-related 




objective hearing tests are 
necessary to confirm these 
results and to evaluate the 













i The first one 
thousand liver 
transplants in Turin: 
a single-center 
experience in Italy. 
Transplant 





center in Turin, 
Italia; highlighting 
the main changes 
that have occurred 
over time 
From 1990 to 2002, 
1000 consecutive 
LT were performed 
in 910 patients, 
mainly cirrhotics. 
Median follow-up of the 
patients was 41 months. 
Overall survival rates at 
1, 5 and 10 years were 
87%, 78% and 72% 
respectively. Survival 
rates obtained in the 
second half of the cases 
(1999–2002) were sign. 
better than those 
obtained in the first half 
(1990–1998) (90% vs. 
83% at 1 year and 81% 
vs. 76% at 5 years). 
Increasing experience in 
liver transplant surgery 
and postoperative care 
allowed standardization of 
the procedure and 
expansion of the activity, 
with parallel improvement 






















dilemma of optimal 
IS of patients with 






Analysed 42 HCV 
infected patients 
who underwent 
cadaveric LT under 
two strategies of IS: 
(1) daily TAC 
throughout and an 




steroid weaning, or 
(2) intraoperative 
ATG and daily TAC 
that was later space 
weaned 
After 36 +/- 4 months, 
patient and graft survival 
in the first group was 
18/19 (94.7%) with no 
examples of clinically 
serious HCV recurrence. 
In the second group, the 
three-year patient 
survival was 52%, and 
graft survival was 
(39%); accelerated 
recurrent hepatitis was 
the principal cause of the 
poor results. 
Since the anti-HCV 
response is unleashed 
when IS is weaned, 




recipients must balance the 
desire to reduce IS or 
induce allotolerance with 













a Comparison of 
Cyclosporine 
Microemulsion and 
Tacrolimus in 39 
















monitoring of blood 
concentration at 2 
hours postdose (C2) 
and tacrolimus-
based IS in LDLT. 
39 Recipients of a  
LDLT of the 495 
patients enrolled in 
LIS2T. Patients 
were randomized to 
CsA-ME(C2 
monitoring) or 






CsA-ME and 16 
received tacrolimus. 
By month 6, 9% CsA-
ME and 19% of those 
receiving tacrolimus had 
lost their graft or died. 9 
episodes of biopsy-
proven ACR were 
reported: CsA-ME group 
(17%) and tacrolimus 
(31%). Serious adverse 
events; infections, CsA-
ME group 61% and 
tacrolimus arm 81%. 12 
patients in the CsA-ME 
arm (52%) and 5 in the 
tacrolimus arm (31%) 
discontinued the study 
prematurely. 
CsA-ME C2 monitoring or 
tacrolimus both offer 
effective protection 
against rejection in LDLT 












 The hepatoadrenal 







As liver failure and 
sepsis are both 
associated with 
increased 




reduced levels of 
apoprotein-1/high-
density lipoprotein, 
we postulated that 
adrenal failure may 
be common in 
patients with liver 
disease. 
The study cohort 
included 340 
patients with liver 
disease. LT at 





was associated with a 
sign. reduction in the 
dose of norepinephrine 
at 24 hrs, whereas the 
dose of norepinephrine 
was sign. higher in those 
patients with adrenal 
failure not treated with 
hydrocorti-sone. In VD 
patients without adrenal 
insufficiency, treatment 
with hydrocortisone did 
not affect vasopressor d. 
Patients with liver failure 
and patients post-LT have 
an exceedingly high 
incidence of adrenal 
failure, which may be 
pathophysiologically 
related to low levels of 
high-density lipoprotein. 
Treatment of patients with 
adrenal failure may 
improve outcome. High 
baseline serum Cortisol 
levels may be a maker of 
disease severity and 













 Analysis of Risk 














between IS and the 
recurrence of HCC 
after LT. 
70 consecutive HCC 
patients who 
underwent LT and 
received 
cyclosporine (CsA)–
based IS. CsA was 
associated with 
steroids in 26 
patients and steroids 
and azathioprine in 
44 patients. 
HCC recurred in 7 
patients (10.0%). 
Different IS schedules or 
the cumulative dosage of 
steroids and azathioprine 
did not influence HCC 
recurrence that was 
associated instead with 
CsA exposure. The 
relationship between 
CsA exposure; various 
clinical. 
High CsA exposure favors 
tumor recurrence; CsA 
blood levels should be 
kept to the effective 
minimum in HCC patients. 
In the presence of 
pathologic and histologic 
risk factors, specific IS 

















Hepatitis C Virus. 
Transplantation, 2004 
Cohort Study Further suggested 
that the efficacy of 
minimalistic 








76 adults;38 HCV−, 
38 HCV+, were 
infused with 30 mg 
alemtuzumab before 
primary cadaveric 
LT and maintained 





The overall incidence of 
rejection was similar 
with the two strategies 
of IS. With follow-ups 
of 14 to 22 months, 
patient and primary graft 
survival in HCV− cases 





versus 71% and 70%, 
respectively, 
With or without HCV, 
62% of the 64 surviving 
lymphoid-depleted 
patients are on spaced IS, 
and four patients receive 
no IS. Lymphoid depletion 
with alemtuzumab and 
minimalistic maintenance 
IS is a practical strategy of 
liver transplantation in 
























and outcomes of 
LAR, of adult LT 
recipients in 
Western Canada 
from 1989 to 2000 
415 patients LAR occurred in 23% of 
patients >180 days 
posttrans- plantation. 
Median follow-up was 
402 days; 79% of LAR 
episodes were graded 
mild. At the time of 
LAR, 33% were on a 
steroid taper. A total of 
73% of LAR episodes 
were treated with pulse 
intravenous steroids, and 
5% were steroid-
resistant. 
There was a trend toward 
increased chronic rejection 
in patients who developed 
LAR. LAR is common 
and occurs after > 1 year 
post transplantation. 
Patients undergoing LT for 
viral etiologies seem to 
have a lower risk of LAR. 
There may be an increased  
risk of chronic rejection in 














s Cardiac Function 
After Orthotopic 
Liver Transplantation 
and the Effects of 
Immunosuppression: 
A Prospective 
Randomized Trial  
Comparing 













cyclosporin (C) IS 
after OLT 
Randomized 40 
adult patients with  
cirrhosis to either T 
or C with 
azathioprine and 
prednisolone IS and 
followed up on them 
for 3 months after  







Abnormalities in cardiac 
function were common  
after OLT and sign. 
deterioration in left 
ventricular diastolic 
function was 
demonstrable up to 3 
months in both patient 
groups. Cardiac function 
was similar in the T and 
C. Reduced heart rate 
variability (HRV) and 
higher mean BNP levels 
were identified in the T 
group. The percentage 
increase in posterior wall 
thickness was higher in 
the T group. 
Cardiac dysfunction as 
shown by worsening 
echocardiographic  
measures of left  
ventricular diastolic 
function and by clinical  
cardiac events is common 
in the first 3 months after  
OLT in patients with 
cirrhosis. HRV and BNP 
values in the T group were 
worse than in the C group, 
but this was not translated 
to an increase in cardiac 













 Evidence of 
Differential Risk for 
Posttransplantation 
Malignancy Based on 
Pretransplantation 










outcomes of de 
novo nonlymphoid 
malignancies  after  
liver transplantation 
from a large single-
center series. 
All patients  
undergoing LT at 
the King’s College 
Hospital, between 
Jan 1988 - Dec 1999 
were analyzed 
retrospectively for 
the development  of 




Of 1,140 patients 
undergoing 1,271 LT, 30 
patients (2.6%) 
developed de novo 
nonlymphoid 
malignancy after LT. 
Skin cancers were the 






carcinoma(n = 2), and 
various other 
malignancies (n = 9).. 
Although the incidence of 
de novo nonlymphoid  
malignancy after LT is  
low, patients who  
underwent LT for 
alcoholic cirrhosis appear 
to have an increased risk 




































101 patients (70 




by iv. bolus 
injection the day of 
transplantation (day 
0) and day 4. In 
addition; triple IS 
therapy. 
At 6 months, the 
incidence of first acute 
biopsy-confirmed 
rejection episodes was 
22.8%. Rejections were 
more frequent in the 
HCV-positive (29%) 
than HCV-negative 
subgroup (20%). No 
rejection episode. Patient 
and graft survival rates 
at 12 months were 
90.1% and 88.1%.5 
malignancies were 
reported at 12 months: 
of these, 3 malignancies 
predated LT surgery. 
Basiliximab caused no 
injection-site reactions, 
anaphylaxis, or cytokine 
release syndrome. 
Compared with earlier 
studies, the addition of 
basiliximab 
immunoprophylaxis to 
triple IS therapy provides 
increased efficacy in 
reducing the incidence of 
acute rejection episodes, 
with no clinically 































term clinical and 
liver histological 
features at and after 
OLT to elucidate 





65 patients who 
underwent OLT for 
hepatitis C and Non 
A Non B hepatitis 
was conducted. 
Histological recurrence 
of HCV was seen in 
43/65 patients, with 
progression in 19 
patients. Histological 
findings in the native 
liver and post-OLT 
biopsy specimen at the 
time of recurrence 
showed no correlation 
with HCV recurrence 
and progression. Patients 
treated with AZA-
containing IS regimens 
experienced less 
recurrence (6/17 v 37/48 
patients) and progression 
(1/17 vs 18/48) than 
those without AZA. 
No difference was seen 
between patients treated 
with cyclosporine vs those 
administered FK506. The 
grade of inflammation in 
the native liver at the time 
of OLT and time of 
recurrence is not 
predictive of progression. 
AZA containing regimens 
reduce histological 
recurrence and progression 


















and Surgery, 1999 
Case report 
study 







allowance is made 















ACR was more likely to 
occur in younger 
patients. ACR was 
increased in transplant 
recipients from donors 
aged <30 and >50 years. 
ACR was less likely to 
occur in patients who 
underwent LT for 
alcoholic liver disease. 
Chronic rejection was 
significantly increased in 




It may be possible to 
individualize IS regimens 























variation in hepatitis 
C virus (HCV) 
viraemia and early 
course of HCV 
infection after liver 
transplantation for 
HCV cirrhosis: the 





case report.  
Evaluate the 
fluctuation of HCV 
viraemia and the 
early course of 
infection, and their 
relation to the type 
of IS in HCV 
transplant patients 
47 HCV transplant 
patients, serum 
HCV RNA were 
taken pretransplant, 
at 1 and 2 weeks, 3 
and 12 months after 
transplant. Initial IS 
triple (cyclosporin, 
azathioprine, predn) 
in 31, double 
(cyclosporin, predn) 
in five, and single 
(cyclosporin or 
tacrolimus) in 11. 
At 3 months, HCV RNA 
levels were higher in 
patients with single than 
with triple or double 
initial therapy. At 12 
months, HCV RNA 
levels correlated only 
with duration of 
prednisolone treatment 
and were relatively 
higher in patients with 
triple compared with 
single initial IS.  
HCV RNA levels at three 
months after transplant are 
higher in patients treated 
with single initial IS 
therapy, but at 12 months 
are higher in patients with 
longer duration of steroid 
treatment. HCV viraemia 
at 12 months seems to be 
particularly important, as 
its levels are strongly 
correlated with the 














 Orthotopic Liver 
Transplantation for 
Hepatitis C: 
Outcome, Effect of 
Immunosuppression, 
and Causes of 
Retransplantation 












(OLT) for end-stage 
liver disease caused 
by hepatitis C virus 
(HCV). 
8-year period 374 
patients underwent 
LT for HCV (79.6% 
received one OLT; 
20.4% required re-
OLT). Median 
follow-up was 2 
years. IS was based 
on cyclosporine in 
190 patients and 
tacrolimus in 132 
patients. 3 group; 
therapy switched 
from cyclosporine 
to tacrolimus or vice 
versa.  
5-year patient survival 
rates were 85%, 81%, 
and 75%, respectively. 
In patients requiring re-
OLT, there was no 
difference in the 1-year 
patient survival rate after 
re-OLT when 
cyclosporine (60%), 
tacrolimus (63%), or 
cyclosporine/ tacrolimus 
(56%) was used for 
primary therapy 
There are no distinct 
advantages to the use of 
cyclosporine vs tacrolimus 
IS when patient and graft 
survival are considered. 
Re-OLT is an important 
option in the treatment of 
recurrent HCV and should 
be performed early in the 
course of recurrent 
disease. Survival after re-
OLT is not distinctively 
affected by cyclosporine 
or tacrolimus primary 
immunotherapy. The 
incidence of re-OLT for 
recurrent HCV or chronic 
rejection is low after either 




11.3 Summary of GRADE  
Reference: Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola 
C, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant 
recipients: 1-year interim results of the HCV-3 study. Liver transplantation : official publication 
of the American Association for the Study of Liver Diseases and the International Liver 
Transplantation Society. 2007;13(11):1521-31. 
Study design: Open-label, randomized, prospective               
Grade - quality   III 
Purpose Material and methods Results Discussion and comments 
Evaluate the effect 
of corticosteroid-
free IS HCV+ LT 
recipients 
following LT. 
LT recipients >18 yr with end-
stage liver disease caused by 
chronic HCV infection. Patients 
excluded from the study: - 
Previously received or receiving 
an organ transplant other than a 
liver. - Received a liver from a 
hepatitis B core antibody–positive 
or a hepatitis C antibody–positive 
donor, or from an ABO blood 
group– incompatible organ donor. 
- Fulminant liver failure, HBV 
surface antigen+.    - Restricted to 
the ICU, or could not be 
administrated a calcineurin 
inhibitor within the first 72 hours 
following LT were.  
Patients received tacrolimus and 
corticosteroids (Arm 1; n=80); 
tacrolimus, corticosteroids, and 
MMF (Arm 2; n=79); or 
daclizumab induction, tacrolimus, 
and MMF (Arm 3; n= 153). 
 At 1 yr, 64.1%, 63.4%, and 
69.4% of patients achieved the 
composite primary endpoint of 
freedom from rejection, 
freedom from HCV 
recurrence, and freedom from 
treatment failure, respectively. 
Excellent patient and graft 
survival did not different 
significant among treatment 
arms. Freedom from HCV 
recurrence at 1 yr was 6.2%, 
6.1%, and 4.3% in Arms 1, 2, 
3. Freedom from rejection was 
sign. higher in Arm 3 vs. 1. 
Defined population: Yes. Is the selection representative for the population: Yes. 
Does responders deviate from not-responders: No. Standardized data analysis: 
The Kaplan-Meier product-limit method. Objective criteria of outcome: A Cox 
proportional hazards model was used to assess the impact of known or suspected 
risk factors on HCV recurrence at day 395. Adequate methods in computer 
analysis: Yes. Defined purpose: Yes. Exclusion and inclusion: Yes. Were Arm 
1, 2 and 3 similar at the beginning: Yes. The randomization has worked: Yes. 
Randomization procedure: 312 patients were enrolled and randomized in a 1:1:2 
ratio among 3 treatment groups. Blinded. For the recurrence analysis, patients 
were censored at the last known time at which a biopsy showed no recurrence of 
hepatitis C infection, if the biopsy was conducted outside of a protocol biopsy 
visit window. Groups treated equally beyond the intervention? Yes. Primary 
endpoint: freedom from treatment failure (death, graft loss, or study withdrawal 
by day 365), freedom from rejection, and freedom from HCV recurrence. 
Results: Recession: There were no withdrawals from Arm 1. Over the first yr of 
follow up, 4 patients withdrew from Arm 2, and 7 from Arm 3. In Arm 2, 3 of 
the 4 patients withdrew consent, while 4 of 7 patients in Arm 3 were lost to 
follow-up. Can results be transferred to practice? Yes. All outcomes measured? 
Yes. Are the benefits worth the disadvantage/costs? Benefits of this regimen 
included a significantly reduced incidence of acute rejection, potentially 
important because of its demonstrated association with HCV disease recurrence. 
Other literature that strengthens the results? Yes; Our findings that are 
consistent with those of some other studies reveal no detectable impact of 
corticosteroid avoidance on HCV recurrence 1 yr after transplanation The 
Authors: All transplant surgeons from different centres in USA. Plausible 







induction is safe 










Reference: Llado L, Fabregat J, Castellote J, Ramos E, Xiol X, Torras J, et al. Impact of 
immunosuppression without steroids on rejection and hepatitis C virus evolution after liver 
transplantation: results of a prospective randomized study. Liver transplantation : official 
publication of the American Association for the Study of Liver Diseases and the International 
Liver Transplantation Society. 2008;14(12):1752-60. 
Study design: Prospective Randomized Study                
Grade - quality   III 
Purpose Material and methods Results Discussion and comments 
Evaluate the influence 
of a steroid-free IS on 
hepatitis C virus 
recurrence 
 
198 LT patients were 
randomized to receive IS with 
basiliximab and cyclosporine, 
either with prednisone (St-
group) or without prednisone 
(NoSt-group).  
The group of 89 HCV-
infected patients got biopsies 
for 2 years after LT. This 
group of HCV patients are the 
patients evaluated in the 
present study. 
The rejection rate was 19% 
(St: 21% vs. NoSt: 17%). 
Patients in the St group had 
more bacterial infections (59% 
vs 38%) 97% of all patients 
had histological HCV 
recurrence. The % of 
accumulated biopsies with gr. 
4 portal inflammation at 6 
months, 1 year, 2 years were, 
23%, 49%, and 49% in the 
NoSt group, vs. 33%, 55%, 
and 69% in the St group. For 
grade 3/4 fibrosis at 6 m, 1 y, 2 
y were 0%, 8%, and 22% for 
the NoSt group, vs. 8%, 19%, 
and 31% for the St group. 
  
 
Defined population: Yes. Is the selection representative for the population: Yes. 
Does responders deviate from not-responders: Patient demographics and baseline 
characteristics of the HCV-infected patients were similar between the groups. Response 
rate: after this 2-year analysis we think that antiviral treatment did not probably had 
influence in our results because rate of response was low and similar between groups. 
Standardized data analysis: Student t test or nonparametric tests as indicated. 
Categorical data were analyzed using the chi-square test or Fisher’s exact test as 
required. Analyses of survival were based on Kaplan-Meier estimates and survival 
curves were compared by means of the log-rank test. A P value <0.05 was 
considered significant. Objective criteria of outcome: Yes, The primary endpoints of 
the study were biopsy-proven acute rejection incidence and patient and graft 
survival. The secondary endpoints were the incidence of adverse events, both 
infections and metabolic decompensations (mainly de novo diabetes mellitus and 
hypertension), and the incidence and severity of hepatitis C recurrence. Defined 
purpose: Yes. Exclusion and inclusion: Yes. Similar groups at the beginning: Yes. 
The randomization has worked: Yes. Randomization procedure: Within each center, 
eligible patients were randomized at the beginning of surgery using sealed envelopes 
and stratification into 2 cohorts: HCV-negative and HCV-positive. Blinded: No. 
Groups treated equally beyond the intervention? Yes. Primary endpoint? Incidence 
of biopsy-proven acute rejection was 19%, with no differences between the groups. 
Results: Actuarial patient and graft survival rates were similar between groups. Can 
results be transferred to practice? Yes. All outcomes measured? Yes. Are the 
benefits worth the disadvantage/costs? Reduces both metabolic complications and 
bacterial infection. Other literature that strengthens the results? Meta-analysis has 
shown that HCV recurrence is lower with steroid avoidance, although no individual 
trial reached statistical significance. Few prospective randomized studies have 
evaluated the influence of steroid-free IS on HCV recurrence; only 2 studies included 
protocol biopsies, and their follow-up was limited to 1 year. Plausible explanations 
on the results: Not accounted for in this article.  
Conclusion 
IS without steroids in 











Year of Data 
sampling: 




Reference: O'Grady JG, Hardy P, Burroughs AK, Elbourne D. Randomized controlled trial of 
tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 
years. American journal of transplantation : official journal of the American Society of Transplantation 
and the American Society of Transplant Surgeons. 2007;7(1):137-41. 
Study design: Randomized Controlled Trial                  
Grade - quality   III 
Purpose Material and methods Results Discussion and comments 
The 1-year results of the 
tacrolimus vs. microem-
ulsified cyclosporin 
(TMC) study found a 
benefit with tacrolimus 
IS after primary LT in 
adults with respect to 
freedom from graft loss 
and immunological 
failure. This is further 2 
years for poststudy 
surveillance. 
The study population 
comprised adults undergoing 
their first liver transplant in 
any of the eight centers in the 
United Kingdom or Republic 
of Ireland.  
Sample size calculation 
indicated that 596 patients 
(298 in each group) would be 
needed to detect a 10% 
difference in the composite 
primary endpoint at 1 year 
from 70–80% (tacrolimus) 
with 80% power and a two-
tail alpha error of 5%. 
 
The data after 3 years confirms 
the significant difference 
between tacrolimus and 
cyclosporin with tacrolimus 
less likely to meet the 
composite primary endpoint 
(log rank p = 0.01; relative risk 
0.75; 95% CI 0.60–0.95; p = 
0.016). However, freedom 
from death or retransplantation 
no longer achieves statistical 
significance (relative risk 0.79; 
95% CI 0.62–1.02; p = 0.065). 
A total of 62.1% of patients 
randomized to tacrolimus were 
alive at 3 years with their 
original graft and still on their 
allocated study medication, as 
compared with only 41.6%in 
the cyclosporin limb (p < 
0.001). No difference was 
detected between tacrolimus 
and cyclosporin in HVC+ 
patients with the available 
data. 
Defined population: Yes. Is the selection representative for the population: 
Yes. Does responders deviate from not-responders: No.  
Standardized data analysis: Kaplan-Meier estimates and comparing 
differences using the log rank test. Other comparisons between treatment 
groups are presented as estimates of effect sizes (relative risks of difference 
of means) with 95% confidence intervals (CIs) and chi-squared, Fisher’s 
exact, Mann-Whitney U or t-tests, where appropriate. Objective criteria of 
outcome: Yes. Defined purpose: Yes. The randomization has worked: Yes. 
Randomization procedure: The integrity of the randomization process was 
preserved for a further 2 years for poststudy surveillance. Patients were 
randomized to either tacrolimus or microemulsified cyclosporin. Blinded? 
Yes. Groups treated equally beyond the intervention? Yes.  
Primary endpoint? By 3 years, patients immunosuppressed with tacrolimus 
were less likely to meet the composite primary endpoint (log rank p = 0.01; 
relative risk 0.75; 95%, CI [0.60 to 0.95] chi-squared p = 0.016). Results: 
During the poststudy surveillance period there were 20 new deaths in the 
tacrolimus limb (8% of those at risk) and 8 new deaths in the cyclosporin 
limb (3.5% of those at risk), resulting in the overall number of deaths being 
71 and 80, respectively. There were 9 deaths at 3 years in the tacrolimus 
group (20%) versus 15 (26%) in the cyclosporin group. Can results be 
transferred to practice? Yes. All outcomes measured: The data collected 
during the poststudy surveillance was not as comprehensive as during the 
first 12 months of the study. In particular, detailed data on rejection 
episodes, drug levels and toxicity that did not lead to a change in the 
immunosuppressive regimen were not collected. Are the benefits worth the 
disadvantage / costs? benefits of tacrolimus-based IS over cyclosporin using C0 
monitoring. Other literature that strengthens the results? Yes. The Authors: 
Members of the UK and the Republic of Ireland Liver Transplant Study Group. 
Plausible explanations on the results: Yes.  
Conclusion 
No difference was found 
between tacrolimus and 
cyclosporin in HCV+ 
patients with the data. 
TMC study confirms 
after 3 years of follow-
up the benefits of tacrol-
imus > cyclosporin. 
Country 
Englend and Ireland.  
Year of Data 
sampling: 
May 1997 – April 1999 
 
IV 
Reference: Therapondos G, Flapan AD, Dollinger MM, Garden OJ, Plevris JN, Hayes PC. Cardiac function after 
orthotopic liver transplantation and the effects of immunosuppression: a prospective randomized trial comparing cyclosporin 
(Neoral) and tacrolimus. Liver transplantation : official publication of the American Association for the Study of Liver Diseases 
and the International Liver Transplantation Society. 2002;8(8):690-700. 
Study design: Prospective randomized trial.                             
Grade - quality   II 
Purpose Material and methods Results Discussion and comments 
Investigated the cardiac 
function of patients on 
tacrolimus (T) compared 
with those on cyclosporin 
(C) IS after OLT. 
Randomized 40 adult patients with 
cirrhosis to either T or C with 
azathioprine and prednisolone IS 
and followed up on them for 3 
months after OLT. All had detailed 
clinical, biochemical, electro-
cardiographic and 
echocardiographic assessments at 
regular intervals. 
Elected to use electrocardiography 
(ECG), detailed echocardiography, 
heart rate variability (HRV) 
indices, and brain natriuretic 
peptide (BNP) levels to study 
cardiac function. HRV indices 
(rMSSD and sNN5O) have been 
shown to be decreased in patients 
with chronic heart failure. 
Patients  with  acute liver failure;  
those undergoing multiple organ  
transplantation or reLT;  and  
patients  with  systemic infection,  
renal  insufficiency, AB0 blood  
group  incompatibility,  and  
previous history  of  malignancy  
were excluded. 
Abnormalities in cardiac function 
were common after OLT and sign. 
deterioration in left ventricular 
diastolic function was demonstrable 
up to 3 months in both patient 
groups. Cardiac function was 
similar in the T and C. Reduced 
HRV and higher mean BNP levels 
were identified in the T group. The 
percentage increase in posterior 
wall thickness was higher in the T 
group. There were three deaths; two 
patients randomized to T, a total of 
11 deaths (including the three 
described previously) from a variety 
of causes. Cardiac events: Two 
patients suffered intraoperative 
cardiac arrests (see later) at 
reperfusion, and a further eight 
patients suffered clinically 
significant cardiac events. These 
were all episodes of pulmonary 
edema within the first 7 post-
operative days (T = 4, C = 4).  
HRV and BNP data may suggest a 
degree of diastolic impairment and 
increase in LV wall thickness in the 
T patients, the clinical relevance of 
these findings remains unclear. 
Defined population: Yes. Is the selection representative for the 
population: Yes. Does responders deviate from not-responders: No. 
Standardized data analysis: All data were analysed on an intention-
to-treat basis up to the point of withdrawal from the study using the 
SPSS statistical package. Student’s t-test was used to compare 
normally distributed variables and chi-square test for categoric 
variables. Objective criteria of outcome: The aforementioned 
investigations were repeated at weeks 1, 2, 4, 8, and 12. Clinical 
event and inpatient stay were recorded. C and T blood levels were 
recorded with target levels. Adequate methods in computer analysis: 
Yes. Defined purpose: Yes. Were C and T-group similar at the 
beginning: Yes. The randomization has worked: Yes. Blinded? No. 
Groups treated equally beyond the intervention? Yes. Results: BNP 
may prove to be a predictor of cardiac complications in this setting, 
although because of the small number of patients, these results 
should be interpreted cautiously. BNP levels were found to be 
significantly higher in the T group from week four onward and may 
reflect a mild degree of LV hypertrophy. Can results be transferred 
to practice? Unclear. All outcomes measured? Yes. Are the benefits 
worth the disadvantage/ costs? Although T may theoretically 
adversely affect the cardiac profile of these patients, it has to be 
remembered that perhaps the benefit gained by its use in patients 
with steroid-resistant rejection (3 in study) outweighs the potential 
complications of its use. Other literature that strengthens the 
results? Yes. Both the European and the United States Multicenter Liver 
Study groups; fewer patients with HT in the T group when compared with 
the C group (European, 35 vs 42%; United States, 47% vs 56%), although 
the differences were not statistically sign. Plausible explanations on the 
results: Might be, because of the small group of patients in this study. 
Conclusion 
Cardiac dysfunction as 
shown by worsening 
echocardiographic  
measures of left  
ventricular diastolic 
function and by clinical  
cardiac events is common 
in the first 3 months after 
OLT in patients with 
cirrhosis. HRV and BNP 
values in the T group 
were worse than in the C 
group, but this was not 
translated to an increase 
in cardiac clinical events 
in this study. 
Country 
Scotland  
Year of Data 
sampling: 
Sept 1996 – June 1998 
 
V 
Reference: Saliba F, Fischer L, de Simone P, Bernhardt P, Bader G, Fung J. Association Between Renal 
Dysfunction and Major Adverse Cardiac Events After Liver Transplantation: Evidence from an International 
Randomized Trial of Everolimus-Based Immunosuppression. Annals of transplantation. 2018;23:751-7. 
Study design: Prospective randomized trial                                   
Grade - quality    
Purpose Material and methods Results Discussion and comments 
Prospective evidence is 
lacking regarding the 
association between renal 
dysfunction and cardio-
vascular events after LT. 
Two-year prospective trail of de 
novo LTx recipients randomized at 
30 days post-transplant to (i) 
everolimus [EVR]/reduced 
tacrolimus [EVR/rTAC] (ii) EVR 
with tacrolimus discontinued 
[TAC Elimination] or (iii) standard 
tacrolimus [TAC Control]. 
Patients were required to have 
eGFR 30 mL/min/1.73 m2 at study 
entry and at the point of 
randomization, with urine protein 
excretion <1.0 g/day. 
 
719 patients were randomized and 
formed the ITT population 
(EVR/rTAC 245, TAC 
Elimination 231, TAC Controls 
243). To evaluate trends in renal 
function from randomization to 
month 24, eGFR values 
documented at each study visit 
(months 1, 2, 3, 4, 5, 6, 9, 12, 18, 
and 24) were used to calculate the 
area under the curve (30), using 
the standard trapezoidal rule. 
 By month 24 post-transplant, 
32/716 patients had major 
cardiac event (4.5%): 4.1%, 
2.2%  and 7.0%  of patients in 
the EVR/rTAC, TAC 
Elimination and TAC Control 
groups, respectively(p=0.043). 
The cumulative eGFR was 119 
706, 123 082, and 105 946 mL 
in the EVR/rTAC, TAC 
Elimination, and TAC Control 
groups, respectively, 
corresponding to a mean eGFR 
AUC of 82.4, 83.0, and 71.9 
mL/min/1.73 m2. Mean eGFR 
AUC was inversely associated 
with time to first major cardiac 
event: [95% CI –0.00000078; –
0.0000024] (p<0.001) 
At randomization, 38.8% of 
patients had diabetes and 22.3% 
had a history of cardiac 
disorders, with a similar 
distribution of both parameters 
between treatment groups.  
Defined population: Yes. Is the selection representative for the 
population: Yes. The study population had similar mean baseline eGFR 
values to the general liver transplant population. Does responders 
deviate from not-responders: Yes. A number of uremic-specific 
cardiovascular risk factors have been identified in the general 
population, including anemia, hyperparathyroidism, hyperhomocystei-
nemia, high lipoprotein(a) levels, and low vitamin C which would be 
expected to apply equally in LTx recipients with poor renal function. 
Standardized data analysis: (see method). Notably, both the EVR/rTAC 
and TAC Elimination groups were associated with a sign. reduction in 
risk for major cardiac events vs standard CNI therapy based on Kaplan-
Meier analysis, but with a more marked effect for the TAC Elimination. 
Objective criteria of outcome: Yes. Adequate methods in computer 
analysis: Yes. Defined purpose: Yes. Exclusion and inclusion: Yes. 
Were group i and ii similar at the beginning: Yes. The randomization 
has worked: Yes. Blinded? Yes. Groups treated equally beyond the 
intervention? Yes. Primary endpoint? Defined. Results: A significant 
direct cardioprotective effect seems unlikely. Despite evidence that 
switching to a mammalian target of mTOR inhibitor reduces left 
ventricular remodelling after heart transplantation, early conversion to 
everolimus has not been found to exert a clinically relevant effect on 
ventricular mass in kidney transplantation. Can results be transferred to 
practice? Yes. All outcomes measured? Yes. Are the benefits worth the 
disadvantage/ costs? It should be noted that although the randomized 
PROTECT study found no increase in biopsy-proven acute rejection 
when CNI elimination was performed more gradually and basiliximab 
induction was given, continuation of a reduced-exposure CNI regimen 
after introducing everolimus may overall be a more appropriate option 
than CNI withdrawal. Other literature that strengthens the results? Yes. 
Organ Procurement and Transplant Network (OPTN).  
Conclusion 
IS regimen based on 
everolimus with TAC 
withdrawal, or to a lesser 
extent TAC reduction, 
improves both renal 
function and the risk of 
major cardiac events 
compared to standard 
treatment with TAC. 
Selection of an 
everolimus-based IS may 
be advantageous in 
avoiding major cardiac 
events in LTx recipients 
with renal dysfunction 
Country 
France, Germany, USA 
Italy, Switzerland. 
Year of Data 
sampling: 
Jan 2008 – April 2012 
 
